



دائرة الصحة  
DEPARTMENT OF HEALTH

# **Burn Services Jawda Guidance**

## **Version 3.2**

**Table of Contents**

|   |           |
|---|-----------|
| <b>Executive Summary .....</b>  | <b>3</b>  |
| <b>About this Guidance.....</b>   | <b>4</b>  |
| <b>Burn Quality Performance Indicators.....</b>   | <b>5</b>  |
| <b>VAE (Ventilator associated event) .....</b>  | <b>5</b>  |
| <b>Percentage of patients who had unplanned intubation .....</b>  | <b>7</b>  |
| <b>Rate of Patients Who Had Deep Vein Thrombosis or Venous Thromboembolism (VTE) .....</b>                        | <b>8</b>  |
| <b>Percentage of patients who had acute kidney injury.....</b>  | <b>9</b>  |
| <b>CLABSI Rate per 1000 Central Line-Days .....</b>   | <b>10</b> |
| <b>CAUTI Rate per 1000 Device Days .....</b>  | <b>13</b> |
| <b>Sepsis / Severe Sepsis Rate per 1000 Discharged Inpatients .....</b>   | <b>15</b> |
| <b>Rate of hospital associated or worsening pressure injury (Stage 2 and above) per 1000 inpatient days .....</b> | <b>16</b> |
| <b>Rate of Healthcare Associated Multidrug-Resistant Organism (MDRO) Bloodstream Infection .....</b>              | <b>19</b> |
| <b>ER under triage rates.....</b>   | <b>21</b> |
| <b>Percent of unplanned Surgical Re-operation in Burn Patients.....</b>   | <b>22</b> |
| <b>Average Length of Stay per Total Body Surface Area (TBSA) .....</b>  | <b>23</b> |
| <b>Incidence of Skin Graft Loss Requiring Re-grafting in Burn Patients.....</b>                                   | <b>24</b> |
| <b>Rate of Burn Wound Infection .....</b>   | <b>25</b> |
| <b>Time to first surgical excision &gt;5 days from admission for Burn Patients with TBSA &gt;=20% .....</b>       | <b>26</b> |
| <b>Rate of Donor Site Infections .....</b>  | <b>27</b> |
| <b>APPENDIX-A-Burn ICD CODES .....</b>  | <b>28</b> |
| <b>APPENDIX-B-Burn Procedure Codes (not limited to).....</b>  | <b>35</b> |
| <b>Appendix C: Non-burn Injuries.....</b>   | <b>37</b> |
| <b>Summary of Changes in Version 2 .....</b>  | <b>38</b> |
| <b>Summary of Changes in Version 3 .....</b>  | <b>38</b> |

## **Executive Summary**

The Department of Health– Abu Dhabi (DOH) is the regulatory body of the healthcare sector in the Emirate of Abu Dhabi and ensures excellence in healthcare for the community by monitoring the health status of its population.

The Emirate of Abu Dhabi is experiencing a substantial growth in the number of hospitals, centers and clinics. This is ranging from school clinics and mobile units to internationally renowned specialist and tertiary academic centers. Although, access and quality of care has improved dramatically over the last couple of decades, mirroring the economic upturn and population boom of Emirate of Abu Dhabi, however challenges remain in addressing further improvements.

The main challenges that are presented with increasingly dynamic population include an aging population with increased expectation for treatment, utilization of technology and diverse workforce leading to increased complexity of healthcare provision in Abu Dhabi. All of this results in an increased and inherent risk to quality and patient safety.

DOH has developed dynamic and comprehensive quality framework in order to bring about improvements across the health sector. This guidance relates to the quality indicators that DOH is mandating the quarterly reporting against by the operating general and specialist hospitals in Abu Dhabi.

The guidance sets out the full definition and method of calculation for patient safety and clinical effectiveness indicators. For enquiries about this guidance, please contact [jawda@DoH.gov.ae](mailto:jawda@DoH.gov.ae)

This document is subject for review and therefore it is advisable to utilize online versions available on the DOH at all times.

Published:    March 2023 Version 1  
                  September 2024 Version 2  
                  December 2024, Version 3  
                  February 2025, Version 3.1  
                  September 2025, Version 3.2

Effective:     Q3 2025, Version 3.2

### About this Guidance

The guidance sets out the definitions and reporting frequency of JAWDA Burn Facilities performance indicators. The Department of Health (DoH), with consultation from local and international expertise of Burn, has developed Burn Performance Indicators that are aimed for assessing the degree to which a provider competently and safely delivers the appropriate clinical services to the patient within the optimal period of time.

The Jawda KPI for burn patients in this guidance include measures to monitor morbidity and mortality in patients undergoing burn treatments. Healthcare providers are the most qualified professionals to develop and evaluate quality of care for burn patients; therefore, it is crucial that clinicians retain a leadership position in defining performance among Burn healthcare providers.

### Who is this guidance for?

All DoH licensed healthcare facilities providing inpatient treatment for burns injury (any degree) in the Emirate of Abu Dhabi.

### How do I follow this guidance?

Each provider will nominate one member of staff to coordinate, collect, monitor and report Burn services quality indicators data as per communicated dates. The nominated healthcare facility lead must in the first instance e-mail their contact details (if different from previous submission) to [JAWDA@doh.gov.ae](mailto:JAWDA@doh.gov.ae) and submit the required quarterly quality performance indicators through Jawda online portal.

### What are the Regulation related to this guidance?

- Legislation establishing the Health Sector
- As per DoH [Policy for Quality and Patient Safety](#) issued January 15<sup>th</sup> 2017, this guidance applies to all DoH Licensed Hospital Healthcare Facilities in the Emirate of Abu Dhabi in accordance with the requirements set out in this Standard.

**Burn Quality Performance Indicators**

**Type: Burn**

**Number: BN001**

|                                 |  |
|---------------------------------|--|
| <b>KPI Description (title):</b> | <b>VAE (Ventilator associated event)</b>   |
| <b>Domain</b>                   | <b>Safety</b>  |
| <b>Indicator Type</b>           | <b>Outcome</b>   |
| <b>Definition</b>               | <p>VAEs are identified by using a combination of objective criteria:</p> <ul style="list-style-type: none"> <li>• Deterioration in respiratory status after a period of stability or improvement on the ventilator,</li> <li>• Evidence of infection or inflammation, and</li> <li>• Laboratory evidence of respiratory infection.</li> </ul> <p>The VAE rate per 1000 ventilator days is calculated by dividing the number of VAEs by the number of ventilator days and multiplying the result by 1000 (ventilator days).</p> <p>NOTE: patient must be mechanically ventilated for at least 4 calendar days to fulfill VAE criteria (where the day of intubation and initiation of mechanical ventilation is day 1). The earliest date of event for VAE (the date of onset of worsening oxygenation) is day 3 of mechanical ventilation.</p>  |
| <b>Calculation</b>              | <p><b>Numerator:</b> Number of patients who received burn treatment</p> <p>Check one:</p> <p><b>*Specific Event:</b></p> <ul style="list-style-type: none"> <li>• VAC Ventilator-Associated Condition,</li> <li>• IVAC Infection related Ventilator-Associated Complication</li> <li>• PVAP Possible Ventilator Associated Pneumonia</li> </ul> <p><b>*Specify Criteria Used:</b></p> <p><b>STEP 1: VAC (≥1 REQUIRED)</b></p> <p>At least one:</p> <ul style="list-style-type: none"> <li>• Daily min FiO<sub>2</sub> increase ≥ 0.20 (20 points) for ≥ 2 days† OR</li> <li>• Daily min PEEP increase ≥ 3 cm H<sub>2</sub>O for ≥ 2 days†</li> <li>• †after 2+ days of stable or decreasing daily minimum values.</li> </ul> <p><b>STEP 2: IVAC</b></p> <ul style="list-style-type: none"> <li>• Both criteria:</li> <li>• Temperature &gt; 38°C or &lt; 36° OR □ White blood cell count ≥ 12,000 or ≤ 4,000 cells/mm<sup>3</sup> AND</li> <li>• A new antimicrobial agent(s) is started, and is continued for ≥ 4 days</li> </ul> <p><b>STEP 3: PVAP</b></p> <p>One of the following criteria is met:</p> <p><b>Criterion #1:</b></p> <ul style="list-style-type: none"> <li>• Positive culture of one of the following specimens, meeting quantitative or semi-quantitative thresholds, without requirement for purulent respiratory secretions:</li> <li>• Endotracheal aspirate □ Lung tissue</li> <li>• Broncho alveolar lavage □ Protected specimen brush</li> </ul> <p>OR</p> <p><b>Criterion #2:</b></p> |

## Jawda Burns Quality Performance Indicators

|                            |   |
|----------------------------|---|
|                            | <ul style="list-style-type: none"> <li>• Purulent respiratory secretions‡ (defined as secretions from the lungs, bronchi, or trachea that contain &gt;25 neutrophils and &lt;10 squamous epithelial cells per low power field [lpf, x100]) plus organism(s) identified from one of the following specimens (to include qualitative culture, or quantitative/semi-quantitative culture without sufficient growth to meet criterion #1)</li> <li>• Sputum</li> <li>• Endotracheal aspirate □ Lung tissue</li> <li>• Broncho alveolar lavage □ Protected specimen brush</li> </ul> <p>OR</p> <p><b>Criterion #3:</b><br/>One of the following positive tests (as outlined in the protocol): ‡</p> <ul style="list-style-type: none"> <li>• Organism(s) identified from pleural fluid</li> <li>• Diagnostic test for Legionella species</li> <li>• Lung histopathology</li> <li>• Diagnostic test for selected viral pathogens ‡collected after 2 days of mechanical ventilation and within +/- 2 days of onset of increase in FiO2 or PEEP.</li> </ul> <p><b><u>Numerator Exclusion:</u></b><br/>If the date of the VAE (i.e., day 1 of the ≥ 2-day period of worsening oxygenation) occurs on the day of transfer/discharge or the next day, indicate the transferring /discharging facility, not the current facility of the patients in the comments box. This patient will be excluded from the numerator count of the hospital facility.<br/>For further information please see surveillance algorithm on page 18 of the VAE module: <a href="https://www.cdc.gov/nhsn/pdfs/pscmanual/10-vae_final.pdf">https://www.cdc.gov/nhsn/pdfs/pscmanual/10-vae_final.pdf</a><br/>patients on high frequency ventilation or extracorporeal life support ,<br/>Non-acute care locations in acute care facilities are not eligible to participate in VAE surveillance<br/>Do not report as VAE, if the date of event (date of onset of worsening oxygenation) is on or after the date of documentation that the patient is being supported for organ donation purposes.<br/>☑ Repeated infection for the same type during 14 days from Date of Event</p> <p><b><u>Denominator:</u></b><br/>Ventilator days: Number of patients who received treatment as an inpatient for burns injury (any degree) (<a href="#">Refer Appendix-A</a>) and were managed with ventilator devices. The ventilator days are collected daily, at the same time each day. These daily counts are summed and only the total for the month is used.</p> <p><b><u>Denominator Inclusion:</u></b><br/>- All ventilator days are counted, including ventilator days for residents on mechanical ventilation for &lt; 3 days.<br/>- Patients undergoing weaning from mechanical ventilation are included in ventilator day counts as long as the patient is receiving support from a mechanical ventilator and is eligible for VAE surveillance</p> |
| <b>Reporting Frequency</b> | Quarterly   |
| <b>Unit Measure</b>        | Rate per 1000 ventilator days   |

## Jawda Burns Quality Performance Indicators

|  |  |
|--|--|
| <b>International comparison if available</b> | American Burn Association<br><a href="#">16d-0615-pq_mk-bqip-definitions-edited-may-2_june-15-2016.pdf (ameriburn.org)</a> |
| <b>Desired Direction</b>                     | Lower is better  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record</li> </ul>   |

Type: Burn

Number: BN002

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Percentage of patients who had unplanned intubation</b>  |
| <b>Domain</b>                                | <b>Safety</b>   |
| <b>Indicator Type</b>                        | <b>Outcome</b>  |
| <b>Definition</b>                            | Patient requires placement of an endotracheal tube and mechanical or assisted ventilation because of the onset of respiratory or cardiac failure manifested by severe respiratory distress, hypoxia, hypercarbia, or respiratory acidosis. In patients who were intubated in the field or Emergency Department, or those intubated for surgery, unplanned intubation occurs if they require reintubation for respiratory failure any time after extubation  |
| <b>Calculation</b>                           | <p><b>Numerator:</b> Number of patients from the denominator, who had an unplanned intubation i.e. if they require reintubation for respiratory failure any time after extubation. (more than one unplanned reintubation just counted as one)</p> <p><b>CPT CODE: 31500</b></p> <p><b>Denominator:</b> Total number of burn inpatients discharged in the measurement period who were extubated at any time during their admission (includes all reasons for initial intubation). <a href="#">(Refer Appendix-A)</a></p> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | American Burn Association<br><a href="#">16d-0615-pq_mk-bqip-definitions-edited-may-2_june-15-2016.pdf (ameriburn.org)</a>  |
| <b>Desired Direction</b>                     | Lower is better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record</li> </ul>  |

Type: Burn

Number: BN003

|  |  |
|--|--|
| <b>KPI Description (title):</b>              | <b>Rate of Patients Who Had Deep Vein Thrombosis or Venous Thromboembolism (VTE)</b>   |
| <b>Domain</b>                                | <b>Safety</b>  |
| <b>Indicator Type</b>                        | <b>Outcome</b>   |
| <b>Definition</b>                            | <p>DVT: The formation, development, or existence of a blood clot or thrombus within the vascular system, which may be coupled with inflammation. This diagnosis must be confirmed by a venogram, ultrasound, or CT.</p> <p>VTE: Lodging of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or the pelvic venous system. The condition must be confirmed by either a V-Q scan interpreted as high probability of pulmonary embolism or a positive pulmonary angiogram, CT angiogram, echocardiogram or on autopsy.</p>   |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Number of patients from the denominator who received burns treatment and had developed deep vein thrombosis or venous thromboembolism during the admission.</p> <ul style="list-style-type: none"> <li> <b>Deep Vein Thrombosis:</b><br/> <b>ICD 10 CM Codes:</b> (I80.201, I80.202, I80.203, I80.209, , I80.211, I80.212, I80.213, I80.219, I80.221, I80.222, I80.223, I80.229, I80.231, I80.232, I80.233, I80.239, I80.291, I80.292, I80.293, I80.299, , I82.401, I82.402, I82.403, I82.409, I82.411, I82.412, I82.413, I82.419, I82.421, I82.422, I82.423, I82.429, I82.431, I82.432, I82.433, I82.439, I82.441, I82.442, I82.443, I82.449, I82.491, I82.492, I82.493, I82.499, I82.4Y1, I82.4Y2, I82.4Y3, I82.4Y9, I82.4Z1, I82.4Z2, I82.4Z3, I82.4Z9, I82.890, I82.90) </li> <li> <b>Pulmonary Embolism:</b><br/> <b>ICD 10 CM Codes:</b> (I26.01, I26.02, I26.09, I26.90, I26.92, I26.99) </li> </ul> <p><b><u>Denominator:</u></b><br/>Total number of discharged inpatients, who received burns injury (any degree) treatment. <b>(Refer Appendix-A)</b></p> <p><b><u>Denominator Exclusion:</u></b><br/>Patients with a principal ICD-10-CM Diagnosis Code or secondary diagnosis present on admission for:</p> <ul style="list-style-type: none"> <li>Deep Vein Thrombosis (please see above)</li> <li>Pulmonary Embolism (please see above)</li> <li>Patients where a procedure for interruption of vena cava occurs before or on the same date as the first operating room procedure (CPT Procedure Code: 37619 Ligation of inferior vena cava, 37191 Insertion of intravascular vena cava filter, endovascular approach including vascular access, vessel selection, and radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance (ultrasound and fluoroscopy), when performed.</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Rate per 1000 patients received burns treatment  |
| <b>International comparison if available</b> | American Burn Association<br><a href="#">16d-0615-pq_mk-bqip-definitions-edited-may-2_june-15-2016.pdf (ameriburn.org)</a>   |
| <b>Desired Direction</b>                     | Lower is better  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>Patient medical record</li> </ul>   |



## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN004

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Percentage of patients who had acute kidney injury</b>   |
| <b>Domain</b>                                | <b>Safety</b>   |
| <b>Indicator Type</b>                        | <b>Outcome</b>  |
| <b>Definition</b>                            | <p>A patient who did not require chronic renal replacement therapy prior to injury, who has worsening renal dysfunction after injury requiring renal replacement therapy.</p> <p>Acute Kidney Injury (stage 3) is an abrupt (within a 48-hour period) reduction of kidney function defined as:</p> <p>Increase in SCr of more than or equal to 3x baseline</p> <p><b>Or</b></p> <p>Increase in SCr to <math>\geq 4\text{mg/dl}</math> (<math>\geq 353.6\mu\text{mol/l}</math>)</p> <p><b>Or</b></p> <p>Initiation of renal replacement therapy</p> <p><b>Or</b></p> <p>Patients <math>&gt;18</math> years, decrease in <math>e\text{ GFR}</math> to <math>&lt; 35\text{ ml/min per }1.73\text{ m}^2</math>.</p> <p><b>And</b></p> <p>Reduction in urine output of <math>&lt; 0.3\text{ ml/kg/hr}</math> for <math>\geq 24\text{ hrs}</math>.</p> <p><b>Or</b></p> <p>Anuria for <math>\geq 12\text{ h}</math></p> |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Number of patients from the denominator who received burn treatment and had developed acute kidney injury requiring renal replacement therapy.</p> <p><b><u>Denominator:</u></b> Total number of discharged inpatients who received burns injury (any degree) treatment. (<a href="#">Refer Appendix-A</a>)</p>   |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | <p>American Burn Association</p> <p><a href="#">16d-0615-pq_mk-bqip-definitions-edited-may-2_june-15-2016.pdf</a> (<a href="#">ameriburn.org</a>)</p>   |
| <b>Desired Direction</b>                     | Lower is better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> </ul>  |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN005

| KPI Description (title): | CLABSI Rate per 1000 Central Line-Days   |
|--------------------------|--|
| Domain                   | Safety   |
| Indicator Type           | Outcome  |
| Definition               | <p><b>Central line-associated BSI (CLABSI):</b> A laboratory-confirmed bloodstream infection (LCBI) where central line (CL) or umbilical catheter (UC) was in place for &gt;2 calendar days on the date of event, with day of device placement being Day 1,<br/> <b>AND</b><br/> A CL or UC was in place on the date of event or the day before. If a CL or UC was in place for &gt;2 calendar days and then removed, the date of event of the LCBI must be the day of discontinuation or the next day. If the patient is admitted or transferred into a facility with an implanted central line (port) in place, and that is the patient's only central line, day of first access in an inpatient location is considered Day1. "Access" is defined as line placement, infusion or withdrawal through the line. Such lines continue to be eligible for CLABSI once they are accessed until they are either discontinued or the day after patient discharged (as per the Transfer Rule). Note that the "de-access" of a port does not result in the patient's removal from CLABSI surveillance.</p> <p><b>Central line:</b> An intravascular catheter that terminates at, close to the heart, or in one of the great vessels that used for infusion, withdrawal of blood, or hemodynamic monitoring. The following are considered great vessels for the purpose of reporting central-line BSI and counting central-line days in the NHSN system:</p> <ol style="list-style-type: none"> <li>8. Aorta</li> <li>9. Pulmonary artery</li> <li>10. Superior vena cava</li> <li>11. Inferior vena cava</li> <li>12. Brachiocephalic veins</li> <li>13. Internal jugular veins</li> <li>14. Subclavian veins</li> <li>15. External iliac veins</li> <li>16. Common iliac veins</li> <li>17. Femoral veins</li> <li>18. In neonates, the umbilical artery/vein.</li> </ol> <p><b>Umbilical catheter:</b> A central vascular device inserted through the umbilical artery or vein in a neonate.</p> |

## Jawda Burns Quality Performance Indicators

|                    |  |
|--------------------|--|
|                    | <p><b>Infusion:</b> The introduction of a solution through a blood vessel via a catheter lumen. This may include continuous infusions such as nutritional fluids or medications, or it may include intermittent infusions such as flushes, IV antimicrobial administration, or blood transfusion or hemodialysis.</p> <p><b>Temporary central line:</b> A non-tunneled, non- implanted catheter.</p> <p><b>Permanent central line:</b> Includes<br/> 19. Tunneled catheters, including certain dialysis catheters<br/> 20. Implanted catheters (including ports)</p> <p><b>Location of Attribution:</b><br/> The inpatient location where the patient was assigned on the date of event is the location of attribution (Exception to Location of Attribution: Transfer Rule: If the date of event is on the date of transfer or discharge, or the next day, the infection is attributed to the transferring/discharging location)</p> <p><b>Date of Event (Event Date):</b><br/> The Date of Event is the date the first element used to meet site-specific infection criterion occurs for the first time within the seven-day infection window period.</p> <p><b>Infection Window Period:</b><br/> Infection Window Period is defined as the 7-days during which all site-specific infection criteria must be met. It includes the day the first positive diagnostic test that is an element of the site-specific infection criterion, was obtained, the 3 calendar days before and the 3 calendar days after.</p> <p><b>Central Line days</b> are the number of patients with an indwelling central lines, are collected daily, at the same time each day.</p> |
| <b>Calculation</b> | <p><b><u>Numerator:</u></b> Number of patients who received burn treatment and had developed CLABSI that is identified during the period selected for surveillance in all inpatient setting.</p> <p><b>Laboratory-Confirmed Bloodstream Infection (LCBI) Criteria to define BSI:</b></p> <p><b>LCBI 1</b><br/> Patient has a recognized pathogen cultured from one or more blood cultures</p> <p><b>AND</b><br/> Organism cultured from blood is not related to an infection at another site</p> <p><b>LCBI 2.</b></p>   |

## Jawda Burns Quality Performance Indicators

|  |   |
|--|---|
|  | <p>Patient has at least one of the following signs or symptoms: fever (&gt;38.0C), chills, or hypotension</p> <p><b>AND</b></p> <p>Organism cultured from blood is not related to an infection at another site.</p> <p><b>AND</b></p> <p>The same common commensal (i.e., diphtheroids [Corynebacterium spp. not C. diphtheriae], Bacillus spp. [not B. anthracis], Propionibacterium spp., coagulase negative staphylococci [including S. epidermidis], viridans group streptococci, Aerococcus spp., and Micrococcus spp.) is cultured from two or more blood cultures drawn on separate occasions.</p> <p><b>LCBI 3 (In Patients ≤ 1 year)</b></p> <p>Patient ≤ 1 year of age has at least one of the following signs or symptoms: fever (&gt;38.0C), hypothermia ((&lt;36.0C), apnea, or bradycardia</p> <p><b>AND</b></p> <p>Organism cultured from blood is not related to an infection at another site,</p> <p><b>AND</b></p> <p>The same common commensal (i.e., diphtheroids [Corynebacterium spp. not C. diphtheriae], Bacillus spp. [not B. anthracis], Propionibacterium spp., coagulase negative staphylococci [including S. epidermidis], viridans group streptococci, Aerococcus spp., and Micrococcus spp.) is cultured from two or more blood cultures drawn on separate occasions</p> <p><b><u>Numerator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• MBI-LCBI</li> <li>• Secondary bloodstream infections</li> <li>• Repeated infection for the same type during 14 days from Date of Event</li> </ul> <p><b><u>Denominator:</u></b> Number of all central line days for patients who received treatment as an inpatient for burn injury (any degree) during the reporting period. (<a href="#">Refer Appendix-A</a>)</p> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Rate per 1000 central line days   |
| <b>International comparison if available</b> | AHRQ and DOH standards<br><a href="http://www.cdc.gov/nhsn/acute-care-hospital/CLABSI/index.html">http://www.cdc.gov/nhsn/acute-care-hospital/CLABSI/index.html</a>   |
| <b>Desired Direction</b>                     | Lower is better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Captured by infection control team</li> <li>• Patient's records</li> <li>• Lab reports</li> <li>• Hospital internal mortality and morbidity</li> </ul>   |

Type: Burn

Number:BN006

|                                 |  |
|---------------------------------|--|
| <b>KPI Description (title):</b> | <b>CAUTI Rate per 1000 Device Days</b>   |
| <b>Domain</b>                   | <b>Safety</b>  |
| <b>Indicator Type</b>           | <b>Outcome</b>   |
| <b>Definition</b>               | <p><b>Catheter-associated UTI (CAUTI):</b> A UTI where an indwelling urinary catheter was in place for &gt;2 calendar days on the date of event, with day of device placement being Day 1 <b>AND</b><br/> An indwelling urinary catheter was in place on the date of event or the day before. If an indwelling urinary catheter was in place for &gt; 2 calendar days and then removed, the date of event for the UTI must be the day of discontinuation or the next day for the UTI to be catheter-associated.</p> <p><b>Indwelling catheter:</b> A drainage tube that is inserted into the urinary bladder through the urethra, is left in place, and is connected to a drainage bag (including leg bags). These devices are also called Foley catheters. Condom or straight in-and-out catheters are not included nor are nephrostomy tubes, ileoconduits, or suprapubic catheters unless a Foley catheter is also present.<br/> Indwelling urethral catheters that are used for intermittent or continuous irrigation are included in CAUTI surveillance.</p> <p><b>Location of Attribution:</b><br/> The inpatient location where the patient was assigned on the date of event is the location of attribution (<b>Exception to Location of Attribution:</b><br/> <i>Transfer Rule:</i> If the date of event is on the date of transfer or discharge, or the next day, the infection is attributed to the transferring/discharging location)</p> <p><b>Date of Event (Event Date):</b> is the date the first element used to meet site-specific infection criterion occurs for the first time within the seven-day infection window period.</p> <p><b>Infection Window Period</b> is defined as the 7-days during which all site-specific infection criteria must be met. It includes the day the first positive diagnostic test that is an element of the site-specific infection criterion, was obtained, the 3 calendar days before and the 3 calendar days after.</p> <p><b>Indwelling catheter days</b> which are the number of patients with an indwelling urinary catheter device, are collected daily, at the same time each day.</p> |

|                           |   |
|---------------------------|---|
|                           | <p>Criteria used to define CAUTI in Adult Patients:</p> <p><b>Criteria 1a.</b></p> <p>Patient must meet 1, 2, and 3 below:</p> <ol style="list-style-type: none"> <li>1. Patient had an indwelling urinary catheter that had been in place for &gt; 2 days on the date of event (day of device placement = Day 1) AND was either: <ul style="list-style-type: none"> <li>• Still present on the date of event, OR</li> <li>• Removed the day before the date of event</li> </ul> </li> <li>2. Patient has at least one of the following signs or symptoms: <ul style="list-style-type: none"> <li>• Fever (&gt;38.0°C)</li> <li>• Suprapubic tenderness</li> <li>• Costovertebral angle pain or tenderness</li> <li>• Urinary urgency</li> <li>• Urinary frequency</li> <li>• Dysuria</li> </ul> </li> <li>3. Patient has a urine culture with no more than two species of organisms, at least one of which is a bacteria of <math>\geq 10^5</math></li> <li>4.</li> <li>5. CFU/ml. All elements of the UTI criterion must occur during the Infection Window Period</li> </ol> <p><b>Criteria used to define CAUTI for Patients <math>\leq 1</math> year:</b></p> <p>Patient must meet 1, 2, and 3 below:</p> <ol style="list-style-type: none"> <li>1. Patient is <math>\leq 1</math> year of age (an indwelling urinary catheter in place for &gt;2 calendar days)</li> <li>2. Patient has at least one of the following signs or symptoms: <ul style="list-style-type: none"> <li>• Fever (&gt;38.0°C)</li> <li>• Hypothermia (&lt;36.0°C)</li> <li>• Apnea</li> <li>• Bradycardia</li> <li>• Lethargy</li> <li>• Vomiting</li> <li>• Suprapubic tenderness</li> </ul> </li> <li>3. Patient has a urine culture with no more than two species of organisms, at least one of which is a bacteria of <math>\geq 10^5</math> CFU/ml. All elements of the SUTI criterion must occur during the Infection Window Period.</li> </ol> |
| <p><b>Calculation</b></p> | <p><b><u>Numerator:</u></b> Number of patients who received burn treatment and had developed CAUTI that is identified during the period selected for surveillance.</p> <p><b><u>Numerator Exclusions:</u></b> Repeated infection for the same type during 14 days from Date of Event</p> <p><b><u>Denominator:</u></b> Total number of catheter device days for all patients who received treatment as inpatient for burns injury (any degree). (<a href="#">Refer Appendix-A</a>)</p> <p><b><u>Denominator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Outpatients</li> </ul> <p>The following organisms cannot be used to meet the UTI definition:</p> <ul style="list-style-type: none"> <li>• Candida species or yeast not otherwise specified</li> <li>• Mold</li> </ul>   |

## Jawda Burns Quality Performance Indicators

|  |   |
|--|---|
|  | <ul style="list-style-type: none"> <li>• Dimorphic fungi or</li> <li>• Parasites</li> <li>• Mixed Flora (urine specimen)</li> </ul>   |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Rate per 1000 urinary catheter days   |
| <b>International comparison if available</b> | AHRQ and DOH standards<br><a href="http://www.cdc.gov/nhsn/acute-care-hospital/CAUTI/index.html">http://www.cdc.gov/nhsn/acute-care-hospital/CAUTI/index.html</a>                                     |
| <b>Desired Direction</b>                     | Lower is better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Captured by infection control team</li> <li>• Patient's Records Chart</li> <li>• Lab Reports</li> <li>• Hospital internal mortality and morbidity</li> </ul> |

Type: Burn

Number: BN007

|                                 |  |
|---------------------------------|--|
| <b>KPI Description (title):</b> | <b>Sepsis / Severe Sepsis Rate per 1000 Discharged Inpatients</b>  |
| <b>Domain</b>                   | <b>Safety</b>  |
| <b>Indicator Type</b>           | <b>Outcome</b>   |
| <b>Definition</b>               | <p>Sepsis and/or Severe Sepsis defined as bacteremia with an obvious source of infection and two or more of the following clinical signs:</p> <ul style="list-style-type: none"> <li>• Temp &gt;38° C or &lt;36° C</li> <li>• WBC count &gt;12,000/mm<sup>3</sup>, or &gt; 20%immature (source of infection)</li> <li>• Hypotension – (Severe Sepsis)</li> <li>• Evidence of hypo perfusion, such as low blood pressure, low urine output; cool extremities; weak peripheral pulse. (Severe Sepsis)</li> <li>• Elevated lactate &gt; 3; serum bicarbonate &lt; 20; or Altered mental status</li> </ul> <p>A patient must have a documented infection as defined by:</p> <ol style="list-style-type: none"> <li>1. Culture positive infection; or</li> <li>2. Pathologic tissue source identified; or</li> <li>3. Clinical response to antimicrobials</li> </ol> <p><b>AND</b> three of the following:</p> <ol style="list-style-type: none"> <li>1. Temperature ≥39° or ≤36.5°C</li> <li>2. Progressive tachycardia <ul style="list-style-type: none"> <li>• Adults ≥110 bpm</li> <li>• Children 2 SD above age-specific norms (85% age-adjusted max heart rate)—use local hospital mean/SD</li> </ul> </li> <li>3. Progressive tachypnea <ul style="list-style-type: none"> <li>• Adults ≥25 bpm not ventilated <ul style="list-style-type: none"> <li>○ Minute ventilation ≥12 l/min ventilated</li> </ul> </li> <li>• Children 2 SD above age-specific norms (85% age-adjusted max respiratory rate)</li> </ul> </li> <li>4. Thrombocytopenia (will not apply until 3days after initial resuscitation) <ul style="list-style-type: none"> <li>• Adults ≤100,000/mcl</li> <li>• Children ≥2 SD below age-specific norms</li> </ul> </li> </ol> |

## Jawda Burns Quality Performance Indicators

|  |  |
|--|--|
|  | <p>5. Hyperglycemia (in the absence of pre-existing diabetes mellitus)</p> <ul style="list-style-type: none"> <li>• Untreated plasma glucose <math>\geq 200</math> mg/dl or equivalent mM/L</li> <li>• Insulin resistance—examples include <ul style="list-style-type: none"> <li>○ <math>\geq 7</math> units of insulin/hr intravenous drip (adults)</li> <li>○ Significant resistance to insulin (<math>\geq 25\%</math> increase in insulin requirements over 24 hours)</li> </ul> </li> </ul> <p>6. VI. Inability to continue enteral feedings <math>\geq 24</math> hours</p> <ul style="list-style-type: none"> <li>• Abdominal distension</li> <li>• Enteral feeding intolerance (residual 150 ml/hr in children or two times feeding rate in adults)</li> <li>• Uncontrollable diarrhea (<math>\geq 2500</math> ml/d for adults or <math>\geq 400</math> ml/d in children)</li> </ul> |
| <b>Calculation</b>                           | <p><b>Numerator:</b> Number of patients who received burn treatment and had developed sepsis / severe sepsis</p> <p><b>Denominator:</b> Total number of discharged inpatients who received treatment as a burn's injury (any degree). (<a href="#">Refer Appendix-A</a>)</p>   |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Rate per 1000 discharged inpatients  |
| <b>International comparison if available</b> | American Burn Association<br><a href="#">16d-0615-pq_mk-bqip-definitions-edited-may-2_june-15-2016.pdf (ameriburn.org)</a>   |
| <b>Desired Direction</b>                     | Lower is better  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital internal adverse event system</li> </ul>   |

Type: Burn

Number:BN008

|                                 |   |
|---------------------------------|---|
| <b>KPI Description (title):</b> | <b>Rate of hospital associated or worsening pressure injury (Stage 2 and above) per 1000 inpatient days</b>   |
| <b>Domain</b>                   | <b>Safety</b>   |
| <b>Indicator Type</b>           | <b>Outcome</b>  |
| <b>Definition</b>               | <p>Tissue loss resulting from pressure exerted by an external object on the patient's skin or by the patient's weight against a surface. The ulcer is staged according to the depth of tissue loss: If the patient has more than one ulcer due to pressure, use this field variable to describe the most severe one.</p> <ul style="list-style-type: none"> <li>• Stage 1: Intact skin with non-blanching erythema</li> <li>• Stage 2: Partial thickness skin loss or blistering that is not due to tape or adhesive.</li> <li>• Stage 3: Full thickness loss of skin. Subcutaneous fat may be visible but not muscle or bone.</li> <li>• Stage 4: Full thickness tissue loss with exposure of muscle or bone.</li> <li>• Unstageable pressure injuries: widely understood to be full-thickness pressure injuries in which the base is obscured by slough and/or eschar.</li> <li>• Bruising indicates deep tissue injury.</li> </ul> |



|                    |  |
|--------------------|--|
| <b>Calculation</b> | <p><b>Numerator:</b> Number of patients who received burn treatment and had developed hospital acquired pressure ulcer injury Stage 2, 3, 4, Unstageable or Deep Tissue Injury (DTI)</p> <p><b>Hospital associated or worsening Pressure Injury (Stage 2 and above)</b><br/> <b>ICD- 10 CM Codes:</b> L89.42, L89.43, L89.44, L89.40, L89.45, L89.812, L89.813, L89.814, L89.819, L89.810, L89.522, L89.523, L89.524, L89.529, L89.520, L89.322, L89.323, L89.324, L89.329, L89.320, L89.022, L89.023, L89.024, L89.029, L89.020, L89.622, L89.623, L89.624, L89.629, L89.620, L89.222, L89.223, L89.224, L89.229, L89.220, L89.142, L89.143, L89.144, L89.149, L89.140, L89.122, L89.123, L89.124, L89.129, L89.120, L89.892, L89.893, L89.894, L89.899, L89.890, L89.512, L89.513, L89.514, L89.519, L89.510, L89.312, L89.313, L89.314, L89.319, L89.310, L89.012, L89.013, L89.014, L89.019, L89.010, L89.612, L89.613, L89.614, L89.619, L89.610, L89.212, L89.213, L89.214, L89.219, L89.210, L89.132, L89.133, L89.134, L89.139, L89.130, L89.112, L89.113, L89.114, L89.119, L89.110, L89.152, L89.153, L89.154, L89.159, L89.150, L89.502, L89.503, L89.504, L89.509, L89.500, L89.302, L89.303, L89.304, L89.309, L89.300, L89.002, L89.003, L89.004, L89.009, L89.000, L89.602, L89.603, L89.604, L89.609, L89.600, L89.202, L89.203, L89.204, L89.209, L89.200, L89.102, L89.103, L89.104, L89.109, L89.100, L89.92, L89.93, L89.94, L89.90, L89.95, L89.46, L89.816, L89.526, L89.326, L89.026, L89.626, L89.226, L89.146, L89.126, L89.896, L89.516, L89.316, L89.016, L89.616, L89.216, L89.136, L89.116, L89.156, L89.506, L89.306, L89.006, L89.606, L89.206, L89.106, L89.96</p> <p><b>Guide on stage is defined below;</b></p> <p><b>Stage 1 Pressure Injury:</b> Non-blanchable erythema of intact skin Intact skin with a localized area of non-blanchable erythema, which may appear differently in darkly pigmented skin. Presence of blanchable erythema or changes in sensation, temperature, or firmness may precede visual changes. Color changes do not include purple or maroon discoloration; these may indicate deep tissue pressure injury.</p> <p><b>Stage 2 Pressure Injury:</b> Partial-thickness skin loss with exposed dermis Partial-thickness loss of skin with exposed dermis. The wound bed is viable, pink or red, moist, and may also present as an intact or ruptured serum-filled blister. Adipose (fat) is not visible and deeper tissues are not visible. Granulation tissue, slough and eschar are not present. These injuries commonly result from adverse microclimate and shear in the skin over the pelvis and shear in the heel. This stage should not be used to describe moisture associated skin damage (MASD) including incontinence associated dermatitis (IAD), intertriginous dermatitis (ITD), medical adhesive related skin injury (MARS), or traumatic wounds (skin tears, burns, abrasions).</p> <p><b>Stage 3 Pressure Injury:</b> Full-thickness skin loss Full-thickness loss of skin, in which adipose (fat) is visible in the ulcer and granulation tissue and epibole (rolled wound edges) are often present. Slough and/or eschar may be visible. The depth of tissue damage varies by anatomical location; areas</p> |
|--------------------|--|

## Jawda Burns Quality Performance Indicators

|                            |  |
|----------------------------|--|
|                            | <p>of significant adiposity can develop deep wounds. Undermining and tunneling may occur. Fascia, muscle, tendon, ligament, cartilage and/or bone are not exposed. If slough or eschar obscures the extent of tissue loss this is an Unstageable Pressure Injury.</p> <p><b>Stage 4 Pressure Injury:</b> Full-thickness skin and tissue loss Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage or bone in the ulcer. Slough and/or eschar may be visible. Epibole (rolled edges), undermining and/or tunneling often occur. Depth varies by anatomical location. If slough or eschar obscures the extent of tissue loss this is an Unstageable Pressure Injury.</p> <p><b>Unstageable Pressure Injury:</b> Obscured full-thickness skin and tissue loss Full-thickness skin and tissue loss in which the extent of tissue damage within the ulcer cannot be confirmed because it is obscured by slough or eschar. If slough or eschar is removed, a Stage 3 or Stage 4 pressure injury will be revealed. Stable eschar (i.e. dry, adherent, intact without erythema or fluctuance) on the heel or ischemic limb should not be softened or removed.</p> <p><b>Deep Tissue Pressure Injury:</b> Persistent non-blanchable deep red, maroon or purple discoloration Intact or non-intact skin with localized area of persistent non-blanchable deep red, maroon, purple discoloration or epidermal separation revealing a dark wound bed or blood filled blister. Pain and temperature change often precede skin color changes. Discoloration may appear differently in darkly pigmented skin. This injury results from intense and/or prolonged pressure and shear forces at the bone-muscle interface. The wound may evolve rapidly to reveal the actual extent of tissue injury, or may resolve without tissue loss. If necrotic tissue, subcutaneous tissue, granulation tissue, fascia, muscle or other underlying structures are visible, this indicates a full thickness pressure injury (Unstageable, Stage 3 or Stage 4). Do not use DTPI to describe vascular, traumatic, neuropathic, or dermatologic conditions</p> <p><b><u>Numerator Inclusions:</u></b></p> <ul style="list-style-type: none"> <li>• All Inpatients (Adult, Pediatric and Neonatal)</li> <li>• Hospital Acquired Pressure Injury (not present or present but with a lower stage on admission to hospital)</li> </ul> <p><b><u>Numerator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Patients with pressure Injury present on admission, that stayed the same stage or improved following hospital stay</li> <li>• Hospital Acquired Pressure Stage I</li> <li>• Day care patients – Medical Management</li> <li>• Day care patients – Procedures</li> </ul> <p><b><u>Denominator:</u></b> Total number of inpatient days should be calculated using ONLY inpatient bed definitions for all patients receiving treatment for burn injury during the reporting period. <a href="#">(Refer Appendix-A)</a></p> |
| <b>Reporting Frequency</b> | Quarterly  |
| <b>Unit Measure</b>        | Rate per 1000 inpatient days   |

## Jawda Burns Quality Performance Indicators

|  |   |
|--|---|
| <b>International comparison if available</b> | American Burn Association<br><a href="#">16d-0615-pg_mk-bqip-definitions-edited-may-2_june-15-2016.pdf (ameriburn.org)</a><br>CQC of UK with modification following discussion with local experts and taking local culture into consideration |
| <b>Desired Direction</b>                     | Lower is better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital internal adverse event system</li> </ul>  |

Type: Burn

Number: BN009

|                                 |   |
|---------------------------------|---|
| <b>KPI Description (title):</b> | <b>Rate of Healthcare Associated Multidrug-Resistant Organism (MDRO) Bloodstream Infection</b>  |
| <b>Domain</b>                   | <b>Safety</b>   |
| <b>Indicator Type</b>           | <b>Outcome</b>  |
| <b>Definition</b>               | <p>Rate of the healthcare-associated MDRO bloodstream infections who meet MDRO definitions during the reporting period.</p> <p><b><u>MDRO Definitions:</u></b></p> <p><b>KPI MDRO-01</b> – Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): Number of <b><i>S. aureus</i></b> isolates cultured from blood specimen that test oxacillin-resistant by standard susceptibility testing methods.</p> <p><b>KPI MDRO-02</b> – Vancomycin-resistant Enterococci (VRE): Number of <b><i>Enterococcus faecalis</i>, <i>Enterococcus faecium</i>, and other <i>Enterococcus</i> species</b> isolates cultured from blood specimen that test resistant to vancomycin by standard susceptibility testing methods.</p> <p><b>KPI MDRO-03</b>- CephR-Klebsiella: Number of <b><i>Klebsiella oxytoca</i> or <i>Klebsiella pneumoniae</i></b> isolates cultured from blood specimen that test non susceptible (specifically, either resistant or intermediate) to at least ONE of the following cephalosporin antibiotics: <i>Ceftazidime</i>, <i>Cefotaxime</i>, <i>Ceftriaxone</i>, or <i>Cefepime</i> by standard susceptibility testing methods</p> <p><b>KPI MDRO-04</b> – Carbapenemase-Producing Organisms (CPO): Number of <b><i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterobacter spp.</i></b> isolates cultured from blood specimen that test resistant by standard susceptibility testing methods to at least ONE of the following carbapenem antibiotics: <i>Carbapenem</i>, <i>Imipenem</i>, <i>Meropenem</i>, <i>Doripenem</i></p> |
| <b>Calculation</b>              | <p><b><u>Numerator:</u></b> Number of patients who received burn treatment have developed MDRO infections that meets MDRO definitions</p> <p><b><u>Numerator Inclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Patient admitted to hospital (Inpatients) only, including ICU and non-ICU inpatient wards</li> <li>• Healthcare Facility-Onset (HO): specimen collected &gt;3 days after admission to the facility (specifically: on or after day 4 after admission, with the admission day counting as day one)</li> <li>• Isolates identified from clinical specimen only (diagnosis and treatment of infection)</li> </ul>   |

## Jawda Burns Quality Performance Indicators

|  |  |
|--|--|
|  | <ul style="list-style-type: none"> <li>Isolates from blood culture specimen only. First isolate per patient only during a 14-day interval.</li> </ul> <p><b><u>Numerator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>Community-Onset (CO): Positive lab tests results for specimens collected at an inpatient location <math>\leq 3</math> days after admission to the facility (i.e., on day 1, 2 or 3 after admission, with the admission day counting as day one).</li> <li>MDROs from patients in an outpatient location (e.g. outpatient clinics, emergency department, home nursing).</li> <li>MDROs from patients in an Inpatient Rehabilitation Facility or Inpatient Psychiatric Facility</li> <li>Duplicate MDRO isolates for the same patient and specimen type (blood) within 14 days after the first MDRO isolate, based on specimen collection date.</li> <li>Isolates identified through screening or active surveillance</li> </ul> <p><b><u>Denominator:</u></b> Total number of inpatient days for all patients received treatment for burn injury (any degree) during the reporting period. (<a href="#">Refer Appendix-A</a>)</p> |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Rate per 1000 inpatient days   |
| <b>International comparison if available</b> | Indicators are based on US CDC NHSN MDRO/CDI Module:<br><a href="http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf">http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf</a><br>OECD Quality indicators, AHRQ, CQC  |
| <b>Desired Direction</b>                     | Lower is better  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>Patient medical record chart</li> <li>Lab test results of all specimen</li> <li>Captured by microbiologist and infection control team/ nursing as part of regular surveillance activities and infection control documentation.</li> </ul>   |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number:BN010

|  |  |
|--|--|
| <b>KPI Description (title):</b>              | <b>ER under triage rates</b>   |
| <b>Domain</b>                                | <b>Patient-Centered</b>  |
| <b>Indicator Type</b>                        | <b>Outcome</b>   |
| <b>Definition</b>                            | Under triage refers to the situation where a patient with a more severe condition is assigned a lower triage level, indicating a lower level of urgency or priority. In the context of burn cases in the emergency department (ED), under triage can have serious consequences as it may delay appropriate and timely treatment for patients with potentially life-threatening burns.  |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Count of all Emergency Department (ED) patients with Total Body Surface Area (TBSA) <math>\geq 20\%</math> burns who do not receive level I management during the measurement period.</p> <p><b><u>Denominator:</u></b> Total Number of Emergency Department patients with Total Body Surface Area (TBSA) <math>\geq 20\%</math> burn during the measurement period.</p> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Patients who Left (ED) Against Medical Advice (LAMA)</li> <li>• Patients who Left Without Being Seen (LWBS)</li> <li>• Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction patients (Refer to Appendix C)</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Percentage   |
| <b>International comparison if available</b> | <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108619/#SD1-oaem-8-103">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108619/#SD1-oaem-8-103</a>  |
| <b>Desired Direction</b>                     | $\leq 10\%$  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> </ul>   |

Type: Burn

Number:BN011

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Percent of unplanned Surgical Re-operation in Burn Patients.</b>   |
| <b>Domain</b>                                | <b>Safety</b>   |
| <b>Indicator Type</b>                        | <b>Outcome</b>  |
| <b>Definition</b>                            | Percent of burn patients that require an emergency/urgent unplanned return to the operating room after initial operative management for a similar or related previous procedure (see Appendix B for procedure).   |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Number of burn patients from the denominator, who require an emergency/urgent unplanned return to the operating room within 48 hours of burn/reconstructive operative management for a similar or related previous procedure, during the same hospitalization.</p> <p><b><u>Numerator Inclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Emergency Cases: Surgical procedures for emergent and critical conditions or injuries that involve an immediate threat to “life, limb, or organ,” requiring emergent surgical intervention within 1 hour.</li> <li>• Urgent Cases: Surgical procedures for urgent but non-critical and non-life-threatening conditions required to be completed within 6 hours.</li> <li>• Related to previous burn procedure.</li> </ul> <p><b><u>Denominator:</u></b><br/>Total number of discharged inpatients with burns injury (any degree) (<a href="#">Refer Appendix A</a>) who received surgical interventions. (Refer <a href="#">Appendix B</a> for Applicable Burn Surgical Procedure Codes)</p> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Inpatients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction inpatients (Refer to Appendix C)</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | n/a   |
| <b>Desired Direction</b>                     | Lower is Better   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital administrative data</li> </ul>  |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number:BN012

|  |  |
|--|--|
| <b>KPI Description (title):</b>              | <b>Average Length of Stay per Total Body Surface Area (TBSA)</b>   |
| <b>Domain</b>                                | <b>Efficiency</b>  |
| <b>Indicator Type</b>                        | <b>Process</b>   |
| <b>Definition</b>                            | Average Length of stay in hospital per TBSA  |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Total number of acute care inpatient days for burn patients with <math>\geq 20\%</math> TBSA) for all patients discharged in the reporting period.</p> <p><b><u>Numerator Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• Patient days for patients in rehab phase who have achieved <math>&gt; 90\%</math> of treated wound healing and no longer requiring surgical intervention OR patient days after the last sedated dressing change.</li> </ul> <p><b><u>Denominator:</u></b> Total TBSA for inpatients that are discharged in the reporting period.</p> <p><b><u>Denominator Inclusion:</u></b></p> <ul style="list-style-type: none"> <li>• All patients with <math>\geq 20\%</math> TBSA discharged alive</li> </ul> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Patients <math>&lt; 20\%</math> TBSA burned</li> <li>• Patients with the discharge disposition of Dead or Left Against Medical Advice (LAMA)</li> <li>• Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction patients (Refer to Appendix C)</li> <li>• Patients who were transferred to another acute care facility for further acute burn injury management</li> <li>• Patients who have full thickness injuries requiring Biodegradable Temporizing Matrix (BTM)/other similar products requiring integration time.</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Average length of stay per TBSA  |
| <b>International comparison if available</b> | <a href="#">Contributors to the length-of-stay trajectory in burn-injured patients - ScienceDirect</a>   |
| <b>Desired Direction</b>                     | 1 day per percent TBSA   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital administrative data</li> </ul>   |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN013

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Incidence of Skin Graft Loss Requiring Re-grafting in Burn Patients</b>  |
| <b>Domain</b>                                | <b>Safety</b>   |
| <b>Indicator Type</b>                        | <b>Outcome</b>  |
| <b>Definition</b>                            | Percent of burn patients who require re-grafting after undergoing skin grafting for burn treatment.   |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Number of burn patients from the denominator that had skin graft loss &gt; 10% of the grafted wound (not TBSA) that required a return to the operating room for re-graft or flap repair.</p> <p><b><u>Denominator:</u></b> Total number of burn inpatients who underwent any skin grafting and discharged during the reporting period.</p> <p><b><u>Denominator Inclusion:</u></b> Patients who required grafting and discharged from acute care within the reporting period.</p> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction (Refer to Appendix C) Patients who were transferred between acute care facilities post initial grafting procedure for further care within 28 days of initial injury</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | Local comparison  |
| <b>Desired Direction</b>                     | <10%  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital administrative data</li> </ul>  |



## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN014

|  |  |
|--|--|
| <b>KPI Description (title):</b>              | <b>Rate of Burn Wound Infection</b>  |
| <b>Domain</b>                                | <b>Safety</b>  |
| <b>Indicator Type</b>                        | <b>Outcome</b>   |
| <b>Definition</b>                            | Percent of burn patients who acquired burn wound infection during inpatient burn treatment.  |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Number of burn patients from the denominator that acquired burn wound infection during admission.</p> <p>Wound infection = at least two of the following criteria:</p> <ul style="list-style-type: none"> <li>- Clinical signs such as localized pain and swelling, spreading erythema and heat at the affected site</li> <li>- Positive bacterial growth of the surface wound swab</li> <li>- Signs of systemic infection indicated by an increase in CRP levels (&gt;10mg/L) together with a body temperature that exceeded 38 degrees C for 48hrs or more where other infection has been excluded</li> </ul> <p><b><u>Denominator:</u></b> Total number of inpatients treated for burns injury and discharged in the reporting period (any degree). <a href="#">(Refer Appendix-A).</a></p> <p><b><u>Denominator Inclusion:</u></b> Patients discharged in the reporting period.</p> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction patients (Refer to Appendix C)</li> <li>• Patients who were admitted and/or transferred with a burn wound infection (as above) on arrival.</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly  |
| <b>Unit Measure</b>                          | Percentage   |
| <b>International comparison if available</b> | <a href="#">2024 NHSN Patient Safety Component Manual (cdc.gov)</a>  |
| <b>Desired Direction</b>                     | <15%   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> <li>• Hospital administrative data</li> </ul>   |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN015

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Time to first surgical excision &gt;5 days from admission for Burn Patients with TBSA <math>\geq</math> 20%</b>  |
| <b>Domain</b>                                | <b>Efficiency</b>   |
| <b>Indicator Type</b>                        | <b>Process</b>  |
| <b>Definition</b>                            | Percentage of patients with burn Total Body Surface Area (TBSA) $\geq$ 20% with Time to first surgical excision >5 days from admission  |
| <b>Calculation</b>                           | <p><b><u>Numerator:</u></b> Total number of Burn patients from the denominator with burn TBSA <math>\geq</math> 20% who had total burn wound excision beyond 5 days from admission.</p> <p><b><u>Denominator:</u></b> Total number of inpatients with burn TBSA <math>\geq</math> 20% and had undergone burn wound excisions and discharged during the reporting period.</p> <p><b><u>Denominator Inclusion:</u></b> Discharged patients in the measurement period.</p> <p><b><u>Denominator Exclusions:</u></b></p> <ul style="list-style-type: none"> <li>• Burn Mass Casualty (more than 3 cases in the same burn event)</li> <li>• Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction patients (Refer to Appendix C)</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721718/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721718/</a>   |
| <b>Desired Direction</b>                     | <10%  |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> </ul>  |

## Jawda Burns Quality Performance Indicators

Type: Burn

Number: BN016

|  |   |
|--|---|
| <b>KPI Description (title):</b>              | <b>Rate of Donor Site Infections</b>  |
| <b>Domain</b>                                | <b>Safety</b>   |
| <b>Indicator Type</b>                        | <b>Outcome</b>  |
| <b>Definition</b>                            | Percentage of burn patients who acquired skin graft donor-site infections within 30 days from skin graft harvest.   |
| <b>Calculation</b>                           | <p><b>Numerator:</b> Total number of Burn patients who acquired an infection at a donor site for a skin graft within 30 days of grafting and who discharged in the reporting period.</p> <p>Wound infection = at least two of the following criteria:</p> <ul style="list-style-type: none"> <li>- Clinical signs such as localized pain and swelling, spreading erythema and heat at the affected site</li> <li>- Positive bacterial growth of the surface wound swab</li> <li>- Signs of systemic infection indicated by an increase in CRP levels (&gt;10mg/L) together with a body temperature that exceeded 38 degrees C for 48hrs or more where other infection has been excluded</li> </ul> <p><b>Denominator:</b> Total number of burn inpatients that underwent skin graft harvesting and were discharged during the reporting period.</p> <p><b>Denominator Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>• Burn reconstruction patients (Refer to Appendix C)</li> <li>• Patients admitted/transferred with donor site infections (as described above) on arrival</li> </ul> |
| <b>Reporting Frequency</b>                   | Quarterly   |
| <b>Unit Measure</b>                          | Percentage  |
| <b>International comparison if available</b> | <a href="#">Skin graft donor site: a procedure for a faster healing - PMC (nih.gov)</a>   |
| <b>Desired Direction</b>                     | <1%   |
| <b>Data Source</b>                           | <ul style="list-style-type: none"> <li>• Patient medical record chart</li> </ul>  |

## Jawda Burns Quality Performance Indicators

### APPENDIX-A-Burn ICD CODES

|          |          |          |          |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|
| T20.00XA | T22.122S | T23.169D | T24.509A | T21.22XA | T22.731S | T23.741D | T25.691A |
| T20.00XD | T22.129A | T23.169S | T24.509D | T21.22XD | T22.732A | T23.741S | T25.691D |
| T20.00XS | T22.129D | T23.171A | T24.509S | T21.22XS | T22.732D | T23.742A | T25.691S |
| T20.011A | T22.129S | T23.171D | T24.511A | T21.23XA | T22.732S | T23.742D | T25.692A |
| T20.011D | T22.131A | T23.171S | T24.511D | T21.23XD | T22.739A | T23.742S | T25.692D |
| T20.011S | T22.131D | T23.172A | T24.511S | T21.23XS | T22.739D | T23.749A | T25.692S |
| T20.012A | T22.131S | T23.172D | T24.512A | T21.24XA | T22.739S | T23.749D | T25.699A |
| T20.012D | T22.132A | T23.172S | T24.512D | T21.24XD | T22.741A | T23.749S | T25.699D |
| T20.012S | T22.132D | T23.179A | T24.512S | T21.24XS | T22.741D | T23.751A | T25.699S |
| T20.019A | T22.132S | T23.179D | T24.519A | T21.25XA | T22.741S | T23.751D | T25.711A |
| T20.019D | T22.139A | T23.179S | T24.519D | T21.25XD | T22.742A | T23.751S | T25.711D |
| T20.019S | T22.139D | T23.191A | T24.519S | T21.25XS | T22.742D | T23.752A | T25.711S |
| T20.02XA | T22.139S | T23.191D | T24.521A | T21.26XA | T22.742S | T23.752D | T25.712A |
| T20.02XD | T22.141A | T23.191S | T24.521D | T21.26XD | T22.749A | T23.752S | T25.712D |
| T20.02XS | T22.141D | T23.192A | T24.521S | T21.26XS | T22.749D | T23.759A | T25.712S |
| T20.03XA | T22.141S | T23.192D | T24.522A | T21.27XA | T22.749S | T23.759D | T25.719A |
| T20.03XD | T22.142A | T23.192S | T24.522D | T21.27XD | T22.751A | T23.759S | T25.719D |
| T20.03XS | T22.142D | T23.199A | T24.522S | T21.27XS | T22.751D | T23.761A | T25.719S |
| T20.04XA | T22.142S | T23.199D | T24.529A | T21.29XA | T22.751S | T23.761D | T25.721A |
| T20.04XD | T22.149A | T23.199S | T24.529D | T21.29XD | T22.752A | T23.761S | T25.721D |
| T20.04XS | T22.149D | T23.401A | T24.529S | T21.29XS | T22.752D | T23.762A | T25.721S |
| T20.05XA | T22.149S | T23.401D | T24.531A | T21.30XA | T22.752S | T23.762D | T25.722A |
| T20.05XD | T22.151A | T23.401S | T24.531D | T21.30XD | T22.759A | T23.762S | T25.722D |
| T20.05XS | T22.151D | T23.402A | T24.531S | T21.30XS | T22.759D | T23.769A | T25.722S |
| T20.06XA | T22.151S | T23.402D | T24.532A | T21.31XA | T22.759S | T23.769D | T25.729A |
| T20.06XD | T22.152A | T23.402S | T24.532D | T21.31XD | T22.761A | T23.769S | T25.729D |
| T20.06XS | T22.152D | T23.409A | T24.532S | T21.31XS | T22.761D | T23.771A | T25.729S |
| T20.07XA | T22.152S | T23.409D | T24.539A | T21.32XA | T22.761S | T23.771D | T25.731A |
| T20.07XD | T22.159A | T23.409S | T24.539D | T21.32XD | T22.762A | T23.771S | T25.731D |
| T20.07XS | T22.159D | T23.411A | T24.539S | T21.32XS | T22.762D | T23.772A | T25.731S |
| T20.09XA | T22.159S | T23.411D | T24.591A | T21.33XA | T22.762S | T23.772D | T25.732A |
| T20.09XD | T22.161A | T23.411S | T24.591D | T21.33XD | T22.769A | T23.772S | T25.732D |
| T20.09XS | T22.161D | T23.412A | T24.591S | T21.33XS | T22.769D | T23.779A | T25.732S |
| T20.10XA | T22.161S | T23.412D | T24.592A | T21.34XA | T22.769S | T23.779D | T25.739A |
| T20.10XD | T22.162A | T23.412S | T24.592D | T21.34XD | T22.791A | T23.779S | T25.739D |
| T20.10XS | T22.162D | T23.419A | T24.592S | T21.34XS | T22.791D | T23.791A | T25.739S |
| T20.111A | T22.162S | T23.419D | T24.599A | T21.35XA | T22.791S | T23.791D | T25.791A |
| T20.111D | T22.169A | T23.419S | T24.599D | T21.35XD | T22.792A | T23.791S | T25.791D |
| T20.111S | T22.169D | T23.421A | T24.599S | T21.35XS | T22.792D | T23.792A | T25.791S |
| T20.112A | T22.169S | T23.421D | T25.011A | T21.36XA | T22.792S | T23.792D | T25.792A |
| T20.112D | T22.191A | T23.421S | T25.011D | T21.36XD | T22.799A | T23.792S | T25.792D |
| T20.112S | T22.191D | T23.422A | T25.011S | T21.36XS | T22.799D | T23.799A | T25.792S |
| T20.119A | T22.191S | T23.422D | T25.012A | T21.37XA | T22.799S | T23.799D | T25.799A |
| T20.119D | T22.192A | T23.422S | T25.012D | T21.37XD | T23.201A | T23.799S | T25.799D |
| T20.119S | T22.192D | T23.429A | T25.012S | T21.37XS | T23.201D | T24.201A | T25.799S |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|
| T20.12XA | T22.192S | T23.429D | T25.019A | T21.39XA | T23.201S | T24.201D | T26.00XA |
| T20.12XD | T22.199A | T23.429S | T25.019D | T21.39XD | T23.202A | T24.201S | T26.00XD |
| T20.12XS | T22.199D | T23.431A | T25.019S | T21.39XS | T23.202D | T24.202A | T26.00XS |
| T20.13XA | T22.199S | T23.431D | T25.021A | T21.60XA | T23.202S | T24.202D | T26.01XA |
| T20.13XD | T22.40XA | T23.431S | T25.021D | T21.60XD | T23.209A | T24.202S | T26.01XD |
| T20.13XS | T22.40XD | T23.432A | T25.021S | T21.60XS | T23.209D | T24.209A | T26.01XS |
| T20.14XA | T22.40XS | T23.432D | T25.022A | T21.61XA | T23.209S | T24.209D | T26.02XA |
| T20.14XD | T22.411A | T23.432S | T25.022D | T21.61XD | T23.211A | T24.209S | T26.02XD |
| T20.14XS | T22.411D | T23.439A | T25.022S | T21.61XS | T23.211D | T24.211A | T26.02XS |
| T20.15XA | T22.411S | T23.439D | T25.029A | T21.62XA | T23.211S | T24.211D | T26.10XA |
| T20.15XD | T22.412A | T23.439S | T25.029D | T21.62XD | T23.212A | T24.211S | T26.10XD |
| T20.15XS | T22.412D | T23.441A | T25.029S | T21.62XS | T23.212D | T24.212A | T26.10XS |
| T20.16XA | T22.412S | T23.441D | T25.031A | T21.63XA | T23.212S | T24.212D | T26.11XA |
| T20.16XD | T22.419A | T23.441S | T25.031D | T21.63XD | T23.219A | T24.212S | T26.11XD |
| T20.16XS | T22.419D | T23.442A | T25.031S | T21.63XS | T23.219D | T24.219A | T26.11XS |
| T20.17XA | T22.419S | T23.442D | T25.032A | T21.64XA | T23.219S | T24.219D | T26.12XA |
| T20.17XD | T22.421A | T23.442S | T25.032D | T21.64XD | T23.221A | T24.219S | T26.12XD |
| T20.17XS | T22.421D | T23.449A | T25.032S | T21.64XS | T23.221D | T24.221A | T26.12XS |
| T20.19XA | T22.421S | T23.449D | T25.039A | T21.65XA | T23.221S | T24.221D | T26.20XA |
| T20.19XD | T22.422A | T23.449S | T25.039D | T21.65XD | T23.222A | T24.221S | T26.20XD |
| T20.19XS | T22.422D | T23.451A | T25.039S | T21.65XS | T23.222D | T24.222A | T26.20XS |
| T20.40XA | T22.422S | T23.451D | T25.091A | T21.66XA | T23.222S | T24.222D | T26.21XA |
| T20.40XD | T22.429A | T23.451S | T25.091D | T21.66XD | T23.229A | T24.222S | T26.21XD |
| T20.40XS | T22.429D | T23.452A | T25.091S | T21.66XS | T23.229D | T24.229A | T26.21XS |
| T20.411A | T22.429S | T23.452D | T25.092A | T21.67XA | T23.229S | T24.229D | T26.22XA |
| T20.411D | T22.431A | T23.452S | T25.092D | T21.67XD | T23.231A | T24.229S | T26.22XD |
| T20.411S | T22.431D | T23.459A | T25.092S | T21.67XS | T23.231D | T24.231A | T26.22XS |
| T20.412A | T22.431S | T23.459D | T25.099A | T21.69XA | T23.231S | T24.231D | T26.30XA |
| T20.412D | T22.432A | T23.459S | T25.099D | T21.69XD | T23.232A | T24.231S | T26.30XD |
| T20.412S | T22.432D | T23.461A | T25.099S | T21.69XS | T23.232D | T24.232A | T26.30XS |
| T20.419A | T22.432S | T23.461D | T25.111A | T21.70XA | T23.232S | T24.232D | T26.31XA |
| T20.419D | T22.439A | T23.461S | T25.111D | T21.70XD | T23.239A | T24.232S | T26.31XD |
| T20.419S | T22.439D | T23.462A | T25.111S | T21.70XS | T23.239D | T24.239A | T26.31XS |
| T20.42XA | T22.439S | T23.462D | T25.112A | T21.71XA | T23.239S | T24.239D | T26.32XA |
| T20.42XD | T22.441A | T23.462S | T25.112D | T21.71XD | T23.241A | T24.239S | T26.32XD |
| T20.42XS | T22.441D | T23.469A | T25.112S | T21.71XS | T23.241D | T24.291A | T26.32XS |
| T20.43XA | T22.441S | T23.469D | T25.119A | T21.72XA | T23.241S | T24.291D | T26.40XA |
| T20.43XD | T22.442A | T23.469S | T25.119D | T21.72XD | T23.242A | T24.291S | T26.40XD |
| T20.43XS | T22.442D | T23.471A | T25.119S | T21.72XS | T23.242D | T24.292A | T26.40XS |
| T20.44XA | T22.442S | T23.471D | T25.121A | T21.73XA | T23.242S | T24.292D | T26.41XA |
| T20.44XD | T22.449A | T23.471S | T25.121D | T21.73XD | T23.249A | T24.292S | T26.41XD |
| T20.44XS | T22.449D | T23.472A | T25.121S | T21.73XS | T23.249D | T24.299A | T26.41XS |
| T20.45XA | T22.449S | T23.472D | T25.122A | T21.74XA | T23.249S | T24.299D | T26.42XA |
| T20.45XD | T22.451A | T23.472S | T25.122D | T21.74XD | T23.251A | T24.299S | T26.42XD |
| T20.45XS | T22.451D | T23.479A | T25.122S | T21.74XS | T23.251D | T24.301A | T26.42XS |
| T20.46XA | T22.451S | T23.479D | T25.129A | T21.75XA | T23.251S | T24.301D | T26.50XA |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|
| T20.46XD | T22.452A | T23.479S | T25.129D | T21.75XD | T23.252A | T24.301S | T26.50XD |
| T20.46XS | T22.452D | T23.491A | T25.129S | T21.75XS | T23.252D | T24.302A | T26.50XS |
| T20.47XA | T22.452S | T23.491D | T25.131A | T21.76XA | T23.252S | T24.302D | T26.51XA |
| T20.47XD | T22.459A | T23.491S | T25.131D | T21.76XD | T23.259A | T24.302S | T26.51XD |
| T20.47XS | T22.459D | T23.492A | T25.131S | T21.76XS | T23.259D | T24.309A | T26.51XS |
| T20.49XA | T22.459S | T23.492D | T25.132A | T21.77XA | T23.259S | T24.309D | T26.52XA |
| T20.49XD | T22.461A | T23.492S | T25.132D | T21.77XD | T23.261A | T24.309S | T26.52XD |
| T20.49XS | T22.461D | T23.499A | T25.132S | T21.77XS | T23.261D | T24.311A | T26.52XS |
| T20.50XA | T22.461S | T23.499D | T25.139A | T21.79XA | T23.261S | T24.311D | T26.60XA |
| T20.50XD | T22.462A | T23.499S | T25.139D | T21.79XD | T23.262A | T24.311S | T26.60XD |
| T20.50XS | T22.462D | T23.501A | T25.139S | T21.79XS | T23.262D | T24.312A | T26.60XS |
| T20.511A | T22.462S | T23.501D | T25.191A | T22.20XA | T23.262S | T24.312D | T26.61XA |
| T20.511D | T22.469A | T23.501S | T25.191D | T22.20XD | T23.269A | T24.312S | T26.61XD |
| T20.511S | T22.469D | T23.502A | T25.191S | T22.20XS | T23.269D | T24.319A | T26.61XS |
| T20.512A | T22.469S | T23.502D | T25.192A | T22.211A | T23.269S | T24.319D | T26.62XA |
| T20.512D | T22.491A | T23.502S | T25.192D | T22.211D | T23.271A | T24.319S | T26.62XD |
| T20.512S | T22.491D | T23.509A | T25.192S | T22.211S | T23.271D | T24.321A | T26.62XS |
| T20.519A | T22.491S | T23.509D | T25.199A | T22.212A | T23.271S | T24.321D | T26.70XA |
| T20.519D | T22.492A | T23.509S | T25.199D | T22.212D | T23.272A | T24.321S | T26.70XD |
| T20.519S | T22.492D | T23.511A | T25.199S | T22.212S | T23.272D | T24.322A | T26.70XS |
| T20.52XA | T22.492S | T23.511D | T25.411A | T22.219A | T23.272S | T24.322D | T26.71XA |
| T20.52XD | T22.499A | T23.511S | T25.411D | T22.219D | T23.279A | T24.322S | T26.71XD |
| T20.52XS | T22.499D | T23.512A | T25.411S | T22.219S | T23.279D | T24.329A | T26.71XS |
| T20.53XA | T22.499S | T23.512D | T25.412A | T22.221A | T23.279S | T24.329D | T26.72XA |
| T20.53XD | T22.50XA | T23.512S | T25.412D | T22.221D | T23.291A | T24.329S | T26.72XD |
| T20.53XS | T22.50XD | T23.519A | T25.412S | T22.221S | T23.291D | T24.331A | T26.72XS |
| T20.54XA | T22.50XS | T23.519D | T25.419A | T22.222A | T23.291S | T24.331D | T26.80XA |
| T20.54XD | T22.511A | T23.519S | T25.419D | T22.222D | T23.292A | T24.331S | T26.80XD |
| T20.54XS | T22.511D | T23.521A | T25.419S | T22.222S | T23.292D | T24.332A | T26.80XS |
| T20.55XA | T22.511S | T23.521D | T25.421A | T22.229A | T23.292S | T24.332D | T26.81XA |
| T20.55XD | T22.512A | T23.521S | T25.421D | T22.229D | T23.299A | T24.332S | T26.81XD |
| T20.55XS | T22.512D | T23.522A | T25.421S | T22.229S | T23.299D | T24.339A | T26.81XS |
| T20.56XA | T22.512S | T23.522D | T25.422A | T22.231A | T23.299S | T24.339D | T26.82XA |
| T20.56XD | T22.519A | T23.522S | T25.422D | T22.231D | T23.301A | T24.339S | T26.82XD |
| T20.56XS | T22.519D | T23.529A | T25.422S | T22.231S | T23.301D | T24.391A | T26.82XS |
| T20.57XA | T22.519S | T23.529D | T25.429A | T22.232A | T23.301S | T24.391D | T26.90XA |
| T20.57XD | T22.521A | T23.529S | T25.429D | T22.232D | T23.302A | T24.391S | T26.90XD |
| T20.57XS | T22.521D | T23.531A | T25.429S | T22.232S | T23.302D | T24.392A | T26.90XS |
| T20.59XA | T22.521S | T23.531D | T25.431A | T22.239A | T23.302S | T24.392D | T26.91XA |
| T20.59XD | T22.522A | T23.531S | T25.431D | T22.239D | T23.309A | T24.392S | T26.91XD |
| T20.59XS | T22.522D | T23.532A | T25.431S | T22.239S | T23.309D | T24.399A | T26.91XS |
| T21.00XA | T22.522S | T23.532D | T25.432A | T22.241A | T23.309S | T24.399D | T26.92XA |
| T21.00XD | T22.529A | T23.532S | T25.432D | T22.241D | T23.311A | T24.399S | T26.92XD |
| T21.00XS | T22.529D | T23.539A | T25.432S | T22.241S | T23.311D | T24.601A | T26.92XS |
| T21.01XA | T22.529S | T23.539D | T25.439A | T22.242A | T23.311S | T24.601D | T27.0XXA |
| T21.01XD | T22.531A | T23.539S | T25.439D | T22.242D | T23.312A | T24.601S | T27.0XXD |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|
| T21.01XS | T22.531D | T23.541A | T25.439S | T22.242S | T23.312D | T24.602A | T27.0XXS |
| T21.02XA | T22.531S | T23.541D | T25.491A | T22.249A | T23.312S | T24.602D | T27.1XXA |
| T21.02XD | T22.532A | T23.541S | T25.491D | T22.249D | T23.319A | T24.602S | T27.1XXD |
| T21.02XS | T22.532D | T23.542A | T25.491S | T22.249S | T23.319D | T24.609A | T27.1XXS |
| T21.03XA | T22.532S | T23.542D | T25.492A | T22.251A | T23.319S | T24.609D | T27.2XXA |
| T21.03XD | T22.539A | T23.542S | T25.492D | T22.251D | T23.321A | T24.609S | T27.2XXD |
| T21.03XS | T22.539D | T23.549A | T25.492S | T22.251S | T23.321D | T24.611A | T27.2XXS |
| T21.04XA | T22.539S | T23.549D | T25.499A | T22.252A | T23.321S | T24.611D | T27.3XXA |
| T21.04XD | T22.541A | T23.549S | T25.499D | T22.252D | T23.322A | T24.611S | T27.3XXD |
| T21.04XS | T22.541D | T23.551A | T25.499S | T22.252S | T23.322D | T24.612A | T27.3XXS |
| T21.05XA | T22.541S | T23.551D | T25.511A | T22.259A | T23.322S | T24.612D | T27.4XXA |
| T21.05XD | T22.542A | T23.551S | T25.511D | T22.259D | T23.329A | T24.612S | T27.4XXD |
| T21.05XS | T22.542D | T23.552A | T25.511S | T22.259S | T23.329D | T24.619A | T27.4XXS |
| T21.06XA | T22.542S | T23.552D | T25.512A | T22.261A | T23.329S | T24.619D | T27.5XXA |
| T21.06XD | T22.549A | T23.552S | T25.512D | T22.261D | T23.331A | T24.619S | T27.5XXD |
| T21.06XS | T22.549D | T23.559A | T25.512S | T22.261S | T23.331D | T24.621A | T27.5XXS |
| T21.07XA | T22.549S | T23.559D | T25.519A | T22.262A | T23.331S | T24.621D | T27.6XXA |
| T21.07XD | T22.551A | T23.559S | T25.519D | T22.262D | T23.332A | T24.621S | T27.6XXD |
| T21.07XS | T22.551D | T23.561A | T25.519S | T22.262S | T23.332D | T24.622A | T27.6XXS |
| T21.09XA | T22.551S | T23.561D | T25.521A | T22.269A | T23.332S | T24.622D | T27.7XXA |
| T21.09XD | T22.552A | T23.561S | T25.521D | T22.269D | T23.339A | T24.622S | T27.7XXD |
| T21.09XS | T22.552D | T23.562A | T25.521S | T22.269S | T23.339D | T24.629A | T27.7XXS |
| T21.10XA | T22.552S | T23.562D | T25.522A | T22.291A | T23.339S | T24.629D | T28.0XXA |
| T21.10XD | T22.559A | T23.562S | T25.522D | T22.291D | T23.341A | T24.629S | T28.0XXD |
| T21.10XS | T22.559D | T23.569A | T25.522S | T22.291S | T23.341D | T24.631A | T28.0XXS |
| T21.11XA | T22.559S | T23.569D | T25.529A | T22.292A | T23.341S | T24.631D | T28.1XXA |
| T21.11XD | T22.561A | T23.569S | T25.529D | T22.292D | T23.342A | T24.631S | T28.1XXD |
| T21.11XS | T22.561D | T23.571A | T25.529S | T22.292S | T23.342D | T24.632A | T28.1XXS |
| T21.12XA | T22.561S | T23.571D | T25.531A | T22.299A | T23.342S | T24.632D | T28.2XXA |
| T21.12XD | T22.562A | T23.571S | T25.531D | T22.299D | T23.349A | T24.632S | T28.2XXD |
| T21.12XS | T22.562D | T23.572A | T25.531S | T22.299S | T23.349D | T24.639A | T28.2XXS |
| T21.13XA | T22.562S | T23.572D | T25.532A | T22.30XA | T23.349S | T24.639D | T28.3XXA |
| T21.13XD | T22.569A | T23.572S | T25.532D | T22.30XD | T23.351A | T24.639S | T28.3XXD |
| T21.13XS | T22.569D | T23.579A | T25.532S | T22.30XS | T23.351D | T24.691A | T28.3XXS |
| T21.14XA | T22.569S | T23.579D | T25.539A | T22.311A | T23.351S | T24.691D | T28.40XA |
| T21.14XD | T22.591A | T23.579S | T25.539D | T22.311D | T23.352A | T24.691S | T28.40XD |
| T21.14XS | T22.591D | T23.591A | T25.539S | T22.311S | T23.352D | T24.692A | T28.40XS |
| T21.15XA | T22.591S | T23.591D | T25.591A | T22.312A | T23.352S | T24.692D | T28.411A |
| T21.15XD | T22.592A | T23.591S | T25.591D | T22.312D | T23.359A | T24.692S | T28.411D |
| T21.15XS | T22.592D | T23.592A | T25.591S | T22.312S | T23.359D | T24.699A | T28.411S |
| T21.16XA | T22.592S | T23.592D | T25.592A | T22.319A | T23.359S | T24.699D | T28.412A |
| T21.16XD | T22.599A | T23.592S | T25.592D | T22.319D | T23.361A | T24.699S | T28.412D |
| T21.16XS | T22.599D | T23.599A | T25.592S | T22.319S | T23.361D | T24.701A | T28.412S |
| T21.17XA | T22.599S | T23.599D | T25.599A | T22.321A | T23.361S | T24.701D | T28.419A |
| T21.17XD | T23.001A | T23.599S | T25.599D | T22.321D | T23.362A | T24.701S | T28.419D |
| T21.17XS | T23.001D | T24.001A | T25.599S | T22.321S | T23.362D | T24.702A | T28.419S |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |          |
|----------|----------|----------|----------|----------|----------|----------|----------|
| T21.19XA | T23.001S | T24.001D | T30.0    | T22.322A | T23.362S | T24.702D | T28.49XA |
| T21.19XD | T23.002A | T24.001S | T30.4    | T22.322D | T23.369A | T24.702S | T28.49XD |
| T21.19XS | T23.002D | T24.002A | T20.20XA | T22.322S | T23.369D | T24.709A | T28.49XS |
| T21.40XA | T23.002S | T24.002D | T20.20XD | T22.329A | T23.369S | T24.709D | T28.5XXA |
| T21.40XD | T23.009A | T24.002S | T20.20XS | T22.329D | T23.371A | T24.709S | T28.5XXD |
| T21.40XS | T23.009D | T24.009A | T20.211A | T22.329S | T23.371D | T24.711A | T28.5XXS |
| T21.41XA | T23.009S | T24.009D | T20.211D | T22.331A | T23.371S | T24.711D | T28.6XXA |
| T21.41XD | T23.011A | T24.009S | T20.211S | T22.331D | T23.372A | T24.711S | T28.6XXD |
| T21.41XS | T23.011D | T24.011A | T20.212A | T22.331S | T23.372D | T24.712A | T28.6XXS |
| T21.42XA | T23.011S | T24.011D | T20.212D | T22.332A | T23.372S | T24.712D | T28.7XXA |
| T21.42XD | T23.012A | T24.011S | T20.212S | T22.332D | T23.379A | T24.712S | T28.7XXD |
| T21.42XS | T23.012D | T24.012A | T20.219A | T22.332S | T23.379D | T24.719A | T28.7XXS |
| T21.43XA | T23.012S | T24.012D | T20.219D | T22.339A | T23.379S | T24.719D | T28.8XXA |
| T21.43XD | T23.019A | T24.012S | T20.219S | T22.339D | T23.391A | T24.719S | T28.8XXD |
| T21.43XS | T23.019D | T24.019A | T20.22XA | T22.339S | T23.391D | T24.721A | T28.8XXS |
| T21.44XA | T23.019S | T24.019D | T20.22XD | T22.341A | T23.391S | T24.721D | T28.90XA |
| T21.44XD | T23.021A | T24.019S | T20.22XS | T22.341D | T23.392A | T24.721S | T28.90XD |
| T21.44XS | T23.021D | T24.021A | T20.23XA | T22.341S | T23.392D | T24.722A | T28.90XS |
| T21.45XA | T23.021S | T24.021D | T20.23XD | T22.342A | T23.392S | T24.722D | T28.911A |
| T21.45XD | T23.022A | T24.021S | T20.23XS | T22.342D | T23.399A | T24.722S | T28.911D |
| T21.45XS | T23.022D | T24.022A | T20.24XA | T22.342S | T23.399D | T24.729A | T28.911S |
| T21.46XA | T23.022S | T24.022D | T20.24XD | T22.349A | T23.399S | T24.729D | T28.912A |
| T21.46XD | T23.029A | T24.022S | T20.24XS | T22.349D | T23.601A | T24.729S | T28.912D |
| T21.46XS | T23.029D | T24.029A | T20.25XA | T22.349S | T23.601D | T24.731A | T28.912S |
| T21.47XA | T23.029S | T24.029D | T20.25XD | T22.351A | T23.601S | T24.731D | T28.919A |
| T21.47XD | T23.031A | T24.029S | T20.25XS | T22.351D | T23.602A | T24.731S | T28.919D |
| T21.47XS | T23.031D | T24.031A | T20.26XA | T22.351S | T23.602D | T24.732A | T28.919S |
| T21.49XA | T23.031S | T24.031D | T20.26XD | T22.352A | T23.602S | T24.732D | T28.99XA |
| T21.49XD | T23.032A | T24.031S | T20.26XS | T22.352D | T23.609A | T24.732S | T28.99XD |
| T21.49XS | T23.032D | T24.032A | T20.27XA | T22.352S | T23.609D | T24.739A | T28.99XS |
| T21.50XA | T23.032S | T24.032D | T20.27XD | T22.359A | T23.609S | T24.739D | T31.0    |
| T21.50XD | T23.039A | T24.032S | T20.27XS | T22.359D | T23.611A | T24.739S | T31.10   |
| T21.50XS | T23.039D | T24.039A | T20.29XA | T22.359S | T23.611D | T24.791A | T31.11   |
| T21.51XA | T23.039S | T24.039D | T20.29XD | T22.361A | T23.611S | T24.791D | T31.20   |
| T21.51XD | T23.041A | T24.039S | T20.29XS | T22.361D | T23.612A | T24.791S | T31.21   |
| T21.51XS | T23.041D | T24.091A | T20.30XA | T22.361S | T23.612D | T24.792A | T31.22   |
| T21.52XA | T23.041S | T24.091D | T20.30XD | T22.362A | T23.612S | T24.792D | T31.30   |
| T21.52XD | T23.042A | T24.091S | T20.30XS | T22.362D | T23.619A | T24.792S | T31.31   |
| T21.52XS | T23.042D | T24.092A | T20.311A | T22.362S | T23.619D | T24.799A | T31.32   |
| T21.53XA | T23.042S | T24.092D | T20.311D | T22.369A | T23.619S | T24.799D | T31.33   |
| T21.53XD | T23.049A | T24.092S | T20.311S | T22.369D | T23.621A | T24.799S | T31.40   |
| T21.53XS | T23.049D | T24.099A | T20.312A | T22.369S | T23.621D | T25.211A | T31.41   |
| T21.54XA | T23.049S | T24.099D | T20.312D | T22.391A | T23.621S | T25.211D | T31.42   |
| T21.54XD | T23.051A | T24.099S | T20.312S | T22.391D | T23.622A | T25.211S | T31.43   |
| T21.54XS | T23.051D | T24.101A | T20.319A | T22.391S | T23.622D | T25.212A | T31.44   |
| T21.55XA | T23.051S | T24.101D | T20.319D | T22.392A | T23.622S | T25.212D | T31.50   |



## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |        |
|----------|----------|----------|----------|----------|----------|----------|--------|
| T21.55XD | T23.052A | T24.101S | T20.319S | T22.392D | T23.629A | T25.212S | T31.51 |
| T21.55XS | T23.052D | T24.102A | T20.32XA | T22.392S | T23.629D | T25.219A | T31.52 |
| T21.56XA | T23.052S | T24.102D | T20.32XD | T22.399A | T23.629S | T25.219D | T31.53 |
| T21.56XD | T23.059A | T24.102S | T20.32XS | T22.399D | T23.631A | T25.219S | T31.54 |
| T21.56XS | T23.059D | T24.109A | T20.33XA | T22.399S | T23.631D | T25.221A | T31.55 |
| T21.57XA | T23.059S | T24.109D | T20.33XD | T22.60XA | T23.631S | T25.221D | T31.60 |
| T21.57XD | T23.061A | T24.109S | T20.33XS | T22.60XD | T23.632A | T25.221S | T31.61 |
| T21.57XS | T23.061D | T24.111A | T20.34XA | T22.60XS | T23.632D | T25.222A | T31.62 |
| T21.59XA | T23.061S | T24.111D | T20.34XD | T22.611A | T23.632S | T25.222D | T31.63 |
| T21.59XD | T23.062A | T24.111S | T20.34XS | T22.611D | T23.639A | T25.222S | T31.64 |
| T21.59XS | T23.062D | T24.112A | T20.35XA | T22.611S | T23.639D | T25.229A | T31.65 |
| T22.00XA | T23.062S | T24.112D | T20.35XD | T22.612A | T23.639S | T25.229D | T31.66 |
| T22.00XD | T23.069A | T24.112S | T20.35XS | T22.612D | T23.641A | T25.229S | T31.70 |
| T22.00XS | T23.069D | T24.119A | T20.36XA | T22.612S | T23.641D | T25.231A | T31.71 |
| T22.011A | T23.069S | T24.119D | T20.36XD | T22.619A | T23.641S | T25.231D | T31.72 |
| T22.011D | T23.071A | T24.119S | T20.36XS | T22.619D | T23.642A | T25.231S | T31.73 |
| T22.011S | T23.071D | T24.121A | T20.37XA | T22.619S | T23.642D | T25.232A | T31.74 |
| T22.012A | T23.071S | T24.121D | T20.37XD | T22.621A | T23.642S | T25.232D | T31.75 |
| T22.012D | T23.072A | T24.121S | T20.37XS | T22.621D | T23.649A | T25.232S | T31.76 |
| T22.012S | T23.072D | T24.122A | T20.39XA | T22.621S | T23.649D | T25.239A | T31.77 |
| T22.019A | T23.072S | T24.122D | T20.39XD | T22.622A | T23.649S | T25.239D | T31.80 |
| T22.019D | T23.079A | T24.122S | T20.39XS | T22.622D | T23.651A | T25.239S | T31.81 |
| T22.019S | T23.079D | T24.129A | T20.60XA | T22.622S | T23.651D | T25.291A | T31.82 |
| T22.021A | T23.079S | T24.129D | T20.60XD | T22.629A | T23.651S | T25.291D | T31.83 |
| T22.021D | T23.091A | T24.129S | T20.60XS | T22.629D | T23.652A | T25.291S | T31.84 |
| T22.021S | T23.091D | T24.131A | T20.611A | T22.629S | T23.652D | T25.292A | T31.85 |
| T22.022A | T23.091S | T24.131D | T20.611D | T22.631A | T23.652S | T25.292D | T31.86 |
| T22.022D | T23.092A | T24.131S | T20.611S | T22.631D | T23.659A | T25.292S | T31.87 |
| T22.022S | T23.092D | T24.132A | T20.612A | T22.631S | T23.659D | T25.299A | T31.88 |
| T22.029A | T23.092S | T24.132D | T20.612D | T22.632A | T23.659S | T25.299D | T31.90 |
| T22.029D | T23.099A | T24.132S | T20.612S | T22.632D | T23.661A | T25.299S | T31.91 |
| T22.029S | T23.099D | T24.139A | T20.619A | T22.632S | T23.661D | T25.311A | T31.92 |
| T22.031A | T23.099S | T24.139D | T20.619D | T22.639A | T23.661S | T25.311D | T31.93 |
| T22.031D | T23.101A | T24.139S | T20.619S | T22.639D | T23.662A | T25.311S | T31.94 |
| T22.031S | T23.101D | T24.191A | T20.62XA | T22.639S | T23.662D | T25.312A | T31.95 |
| T22.032A | T23.101S | T24.191D | T20.62XD | T22.641A | T23.662S | T25.312D | T31.96 |
| T22.032D | T23.102A | T24.191S | T20.62XS | T22.641D | T23.669A | T25.312S | T31.97 |
| T22.032S | T23.102D | T24.192A | T20.63XA | T22.641S | T23.669D | T25.319A | T31.98 |
| T22.039A | T23.102S | T24.192D | T20.63XD | T22.642A | T23.669S | T25.319D | T31.99 |
| T22.039D | T23.109A | T24.192S | T20.63XS | T22.642D | T23.671A | T25.319S | T32.0  |
| T22.039S | T23.109D | T24.199A | T20.64XA | T22.642S | T23.671D | T25.321A | T32.10 |
| T22.041A | T23.109S | T24.199D | T20.64XD | T22.649A | T23.671S | T25.321D | T32.11 |
| T22.041D | T23.111A | T24.199S | T20.64XS | T22.649D | T23.672A | T25.321S | T32.20 |
| T22.041S | T23.111D | T24.401A | T20.65XA | T22.649S | T23.672D | T25.322A | T32.21 |
| T22.042A | T23.111S | T24.401D | T20.65XD | T22.651A | T23.672S | T25.322D | T32.22 |
| T22.042D | T23.112A | T24.401S | T20.65XS | T22.651D | T23.679A | T25.322S | T32.30 |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |        |
|----------|----------|----------|----------|----------|----------|----------|--------|
| T22.042S | T23.112D | T24.402A | T20.66XA | T22.651S | T23.679D | T25.329A | T32.31 |
| T22.049A | T23.112S | T24.402D | T20.66XD | T22.652A | T23.679S | T25.329D | T32.32 |
| T22.049D | T23.119A | T24.402S | T20.66XS | T22.652D | T23.691A | T25.329S | T32.33 |
| T22.049S | T23.119D | T24.409A | T20.67XA | T22.652S | T23.691D | T25.331A | T32.40 |
| T22.051A | T23.119S | T24.409D | T20.67XD | T22.659A | T23.691S | T25.331D | T32.41 |
| T22.051D | T23.121A | T24.409S | T20.67XS | T22.659D | T23.692A | T25.331S | T32.42 |
| T22.051S | T23.121D | T24.411A | T20.69XA | T22.659S | T23.692D | T25.332A | T32.43 |
| T22.052A | T23.121S | T24.411D | T20.69XD | T22.661A | T23.692S | T25.332D | T32.44 |
| T22.052D | T23.122A | T24.411S | T20.69XS | T22.661D | T23.699A | T25.332S | T32.50 |
| T22.052S | T23.122D | T24.412A | T20.70XA | T22.661S | T23.699D | T25.339A | T32.51 |
| T22.059A | T23.122S | T24.412D | T20.70XD | T22.662A | T23.699S | T25.339D | T32.52 |
| T22.059D | T23.129A | T24.412S | T20.70XS | T22.662D | T23.701A | T25.339S | T32.53 |
| T22.059S | T23.129D | T24.419A | T20.711A | T22.662S | T23.701D | T25.391A | T32.54 |
| T22.061A | T23.129S | T24.419D | T20.711D | T22.669A | T23.701S | T25.391D | T32.55 |
| T22.061D | T23.131A | T24.419S | T20.711S | T22.669D | T23.702A | T25.391S | T32.60 |
| T22.061S | T23.131D | T24.421A | T20.712A | T22.669S | T23.702D | T25.392A | T32.61 |
| T22.062A | T23.131S | T24.421D | T20.712D | T22.691A | T23.702S | T25.392D | T32.62 |
| T22.062D | T23.132A | T24.421S | T20.712S | T22.691D | T23.709A | T25.392S | T32.63 |
| T22.062S | T23.132D | T24.422A | T20.719A | T22.691S | T23.709D | T25.399A | T32.64 |
| T22.069A | T23.132S | T24.422D | T20.719D | T22.692A | T23.709S | T25.399D | T32.65 |
| T22.069D | T23.139A | T24.422S | T20.719S | T22.692D | T23.711A | T25.399S | T32.66 |
| T22.069S | T23.139D | T24.429A | T20.72XA | T22.692S | T23.711D | T25.611A | T32.70 |
| T22.091A | T23.139S | T24.429D | T20.72XD | T22.699A | T23.711S | T25.611D | T32.71 |
| T22.091D | T23.141A | T24.429S | T20.72XS | T22.699D | T23.712A | T25.611S | T32.72 |
| T22.091S | T23.141D | T24.431A | T20.73XA | T22.699S | T23.712D | T25.612A | T32.73 |
| T22.092A | T23.141S | T24.431D | T20.73XD | T22.70XA | T23.712S | T25.612D | T32.74 |
| T22.092D | T23.142A | T24.431S | T20.73XS | T22.70XD | T23.719A | T25.612S | T32.75 |
| T22.092S | T23.142D | T24.432A | T20.74XA | T22.70XS | T23.719D | T25.619A | T32.76 |
| T22.099A | T23.142S | T24.432D | T20.74XD | T22.711A | T23.719S | T25.619D | T32.77 |
| T22.099D | T23.149A | T24.432S | T20.74XS | T22.711D | T23.721A | T25.619S | T32.80 |
| T22.099S | T23.149D | T24.439A | T20.75XA | T22.711S | T23.721D | T25.621A | T32.81 |
| T22.10XA | T23.149S | T24.439D | T20.75XD | T22.712A | T23.721S | T25.621D | T32.82 |
| T22.10XD | T23.151A | T24.439S | T20.75XS | T22.712D | T23.722A | T25.621S | T32.83 |
| T22.10XS | T23.151D | T24.491A | T20.76XA | T22.712S | T23.722D | T25.622A | T32.84 |
| T22.111A | T23.151S | T24.491D | T20.76XD | T22.719A | T23.722S | T25.622D | T32.85 |
| T22.111D | T23.152A | T24.491S | T20.76XS | T22.719D | T23.729A | T25.622S | T32.86 |
| T22.111S | T23.152D | T24.492A | T20.77XA | T22.719S | T23.729D | T25.629A | T32.87 |
| T22.112A | T23.152S | T24.492D | T20.77XD | T22.721A | T23.729S | T25.629D | T32.88 |
| T22.112D | T23.159A | T24.492S | T20.77XS | T22.721D | T23.731A | T25.629S | T32.90 |
| T22.112S | T23.159D | T24.499A | T20.79XA | T22.721S | T23.731D | T25.631A | T32.91 |
| T22.119A | T23.159S | T24.499D | T20.79XD | T22.722A | T23.731S | T25.631D | T32.92 |
| T22.119D | T23.161A | T24.499S | T20.79XS | T22.722D | T23.732A | T25.631S | T32.93 |
| T22.119S | T23.161D | T24.501A | T21.20XA | T22.722S | T23.732D | T25.632A | T32.94 |
| T22.121A | T23.161S | T24.501D | T21.20XD | T22.729A | T23.732S | T25.632D | T32.95 |
| T22.121D | T23.162A | T24.501S | T21.20XS | T22.729D | T23.739A | T25.632S | T32.96 |
| T22.121S | T23.162D | T24.502A | T21.21XA | T22.729S | T23.739D | T25.639A | T32.97 |

## Jawda Burns Quality Performance Indicators

|          |          |          |          |          |          |          |        |
|----------|----------|----------|----------|----------|----------|----------|--------|
| T22.122A | T23.162S | T24.502D | T21.21XD | T22.731A | T23.739S | T25.639D | T32.98 |
| T22.122D | T23.169A | T24.502S | T21.21XS | T22.731D | T23.741A | T25.639S | T32.99 |

### APPENDIX-B-Burn Procedure Codes (not limited to)

| CPT          | CPT Description FY2021   |
|--------------|--|
| <b>15852</b> | Dressing change (for other than burns) under anesthesia (other than local)   |
| <b>16000</b> | Initial treatment, first degree burn, when no more than local treatment is required  |
| <b>16020</b> | Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface area)   |
| <b>16025</b> | Dressings and/or debridement of partial-thickness burns, initial or subsequent; medium (eg, whole face or whole extremity, or 5% to 10% total body surface area)   |
| <b>16030</b> | Dressings and/or debridement of partial-thickness burns, initial or subsequent; large (eg, more than 1 extremity, or greater than 10% total body surface area)   |
| <b>15040</b> | Harvest of skin for tissue cultured skin autograft, 100 sq cm or less  |
| <b>15050</b> | Pinch graft, single or multiple, to cover small ulcer, tip of digit, or other minimal open area (except on face), up to defect size 2 cm diameter  |
| <b>15100</b> | Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)   |
| <b>15101</b> | Split-thickness autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)   |
| <b>15110</b> | Epidermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children  |
| <b>15111</b> | Epidermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)   |
| <b>15115</b> | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children  |
| <b>15116</b> | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)       |
| <b>15120</b> | Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)   |
| <b>15121</b> | Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure) |
| <b>15130</b> | Dermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children   |
| <b>15131</b> | Dermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)  |
| <b>15135</b> | Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children   |
| <b>15136</b> | Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)          |
| <b>15150</b> | Tissue cultured skin autograft, trunk, arms, legs; first 25 sq cm or less  |

## Jawda Burns Quality Performance Indicators

|              |  |
|--------------|--|
| <b>15151</b> | Tissue cultured skin autograft, trunk, arms, legs; additional 1 sq cm to 75 sq cm (List separately in addition to code for primary procedure)  |
| <b>15152</b> | Tissue cultured skin autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)  |
| <b>15155</b> | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 25 sq cm or less  |
| <b>15156</b> | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; additional 1 sq cm to 75 sq cm (List separately in addition to code for primary procedure)  |
| <b>15157</b> | Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)                            |
| <b>15200</b> | Full thickness graft, free, including direct closure of donor site, trunk; 20 sq cm or less  |
| <b>15201</b> | Full thickness graft, free, including direct closure of donor site, trunk; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)   |
| <b>15220</b> | Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; 20 sq cm or less   |
| <b>15221</b> | Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)  |
| <b>15240</b> | Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands, and/or feet; 20 sq cm or less  |
| <b>15241</b> | Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands, and/or feet; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)   |
| <b>15260</b> | Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; 20 sq cm or less   |
| <b>15261</b> | Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)  |
| <b>15271</b> | Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area   |
| <b>15272</b> | Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)  |
| <b>15273</b> | Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children   |
| <b>15274</b> | Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure) |
| <b>15275</b> | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area   |
| <b>15276</b> | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)                    |
| <b>15277</b> | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children   |

## Jawda Burns Quality Performance Indicators

|              |  |
|--------------|--|
| <b>15278</b> | Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure) |
| <b>15760</b> | Graft; composite (eg, full thickness of external ear or nasal ala), including primary closure, donor area  |
| <b>15769</b> | Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)  |
| <b>15770</b> | Graft; derma-fat-fascia  |
| <b>14350</b> | Filletted finger or toe flap, including preparation of recipient site  |
| <b>15600</b> | Delay of flap or sectioning of flap (division and inset); at trunk   |
| <b>15610</b> | Delay of flap or sectioning of flap (division and inset); at scalp, arms, or legs  |
| <b>15620</b> | Delay of flap or sectioning of flap (division and inset); at forehead, cheeks, chin, neck, axillae, genitalia, hands, or feet  |
| <b>15630</b> | Delay of flap or sectioning of flap (division and inset); at eyelids, nose, ears, or lips  |
| <b>15650</b> | Transfer, intermediate, of any pedicle flap (eg, abdomen to wrist, Walking tube), any location   |
| <b>15730</b> | Midface flap (ie, zygomaticofacial flap) with preservation of vascular pedicle(s)  |
| <b>15731</b> | Forehead flap with preservation of vascular pedicle (eg, axial pattern flap, paramedian forehead flap)   |
| <b>15733</b> | Muscle, myocutaneous, or fasciocutaneous flap; head and neck with named vascular pedicle (ie, buccinators, genioglossus, temporalis, masseter, sternocleidomastoid, levator scapulae)  |
| <b>15734</b> | Muscle, myocutaneous, or fasciocutaneous flap; trunk   |
| <b>15736</b> | Muscle, myocutaneous, or fasciocutaneous flap; upper extremity   |
| <b>15738</b> | Muscle, myocutaneous, or fasciocutaneous flap; lower extremity   |
| <b>15740</b> | Flap; island pedicle requiring identification and dissection of an anatomically named axial vessel   |
| <b>15750</b> | Flap; neurovascular pedicle  |
| <b>15756</b> | Free muscle or myocutaneous flap with microvascular anastomosis  |
| <b>15757</b> | Free skin flap with microvascular anastomosis  |
| <b>15758</b> | Free fascial flap with microvascular anastomosis   |

### Appendix C: Non-burn Injuries

| Friction/Shearing   | Traumatic injuries   | Cold Injury   | Rash/Skin Infection   | Inhalation Injury Only  | Burn reconstruction  |
|---|--|---|---|---|--|
| <ul style="list-style-type: none"> <li>• Road Rash / Gravel Burn</li> <li>• Treadmill</li> <li>• Tire</li> <li>• Other</li> </ul> | <ul style="list-style-type: none"> <li>• Soft Tissue Degloving</li> <li>• Morel-Lavallee Lesion (MLL)</li> <li>• Crush Injury</li> <li>• Insect or Animal Bite</li> <li>• Partial Amputation</li> <li>• Other</li> </ul> | <ul style="list-style-type: none"> <li>• Cold Injury</li> <li>• Frostbite</li> <li>• Other</li> </ul> | <ul style="list-style-type: none"> <li>• Toxic Epidermal Necrolysis/ Stevens-Johnson Syndrome</li> <li>• Skin Necrosis (Purpura Fulminans, Septic Skin Necrosis, DIC)</li> <li>• Necrotizing Soft Tissue</li> <li>• Pemphigus/Pemphigoid</li> <li>• Calciphylaxis</li> <li>• Hidradenitis</li> <li>• Other</li> </ul> | <ul style="list-style-type: none"> <li>• House/Residence</li> <li>• Industrial</li> <li>• Chemical/Alkaline</li> <li>• Chemical Acid</li> <li>• Vehicle</li> <li>• Steam</li> <li>• Gas Explosion</li> <li>• Other</li> </ul> | Burn reconstruction cases admitted or operated as day case >28 days after injury and usually with additional diagnosis codes: L90.5 or L91.0 |

## Summary of Changes in Version 2

| KPI #         | Changes  |
|---------------|--|
| BN010 – BN016 | <ul style="list-style-type: none"> <li>Added NEW Burn KPIs</li> </ul>  |
| APPENDIX B    | <ul style="list-style-type: none"> <li>Added Appendix B for Burn procedure codes</li> </ul>  |
| BN001-BN008   | <ul style="list-style-type: none"> <li>Remove Denominator exclusion: Discharge against medical advice</li> </ul>   |
| BN002         | <ul style="list-style-type: none"> <li>Added in the Numerator: (more than one unplanned reintubation just counted as one)</li> <li>In the denominator replaced the word intubation with extubation.</li> </ul>                               |
| BN006         | <ul style="list-style-type: none"> <li>Replace <math>\geq 105</math> to <math>\geq 10^5</math> CFU/ml</li> </ul>   |
| BN007         | <ul style="list-style-type: none"> <li>Rephrase the denominator sentence- Total number of discharge patients who received treatment as a burns injury (any degree).</li> <li>Added Unit Measure: Rate per 1000 discharge patients</li> </ul> |
| BN001-BN0016  | <ul style="list-style-type: none"> <li>Wherever applicable added appendix A and B as Link form.</li> </ul>   |

## Summary of Changes in Version 3

| KPI #       | Changes effective Q4 2024   |
|-------------|---|
| BN001-BN016 | Revised All the domain and indicator type based on IOM website  |
| BN002       | Denominator changed from “Total number of patients who received treatment as an inpatient for burns injury (any degree) and who were extubated” to “Total number of burn inpatients discharged in the measurement period who were extubated at any time during their admission (includes all reasons for initial intubation).” (Refer Appendix-A) |
| BN003       | Denominator changed from “Total number of patients who received treatment as an inpatient for burns injury (any degree) to “Total number of discharged inpatients who received burns injury (any degree) treatment”. (Refer Appendix-A)   |
| BN004       | Denominator changed from “Total number of patients who received treatment as an inpatient for burns injury (any degree) to “Total number of discharged inpatients who received burns injury (any degree) treatment”. (Refer Appendix-A)   |
| BN010       | Added Denominator Exclusions: <ul style="list-style-type: none"> <li>Patients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>Burn reconstruction patients (Refer to Appendix C)</li> </ul>                                       |
| BN011       | Denominator changed from “All Burn patients that required surgical interventions. See Appendix B for Applicable Burn Surgical Procedure Codes” to “Total number of discharged inpatients with burns injury (any degree) (Refer Appendix A) who received surgical interventions. (Refer Appendix B for Applicable Burn Surgical Procedure Codes)”  |
| BN012       | Added Denominator Exclusion: <ul style="list-style-type: none"> <li>Patients who was transferred to another acute care facility for further acute burn injury management.</li> </ul> Unit Measure update: Median length of stay per TBSA  |
| BN013       | Added Denominator Exclusion: <ul style="list-style-type: none"> <li>Patients who were transferred between acute care facilities post initial grafting procedure for further care within 28 days of initial injury</li> </ul>  |
| BN014       | Added Denominator Exclusion: <ul style="list-style-type: none"> <li>Patients who were admitted and/or transferred with a burn wound infection (as above) on arrival.</li> </ul>   |

## Jawda Burns Quality Performance Indicators

|               |   |
|---------------|---|
| BN016         | Added Denominator Exclusion: <ul style="list-style-type: none"> <li>Patients admitted/transferred with donor site infections (as described above) on arrival</li> </ul>   |
| BN011 – BN016 | Added Denominator Exclusions: <ul style="list-style-type: none"> <li>Inpatients with non-burn injuries including friction/shearing, traumatic injuries, cold injury, rash/skin infection, inhalation injury only (Refer to Appendix C)</li> <li>Burn reconstruction inpatients (Refer to Appendix C)</li> </ul> |
| Appendix C    | New appendix has been added that lists the condition included in the non-burn injuries.   |

### Summary of Changes in Version 3.1

| KPI # | Changes  |
|-------|--|
| BN009 | <ul style="list-style-type: none"> <li>Moved Denominator Exclusions to Numerator Exclusions</li> </ul> |

### Summary of Changes in Version 3.2

| KPI # | Changes   |
|-------|---|
| BN003 | Edited title from “percentage” to “rate”.   |
| BN012 | <ul style="list-style-type: none"> <li>Title, definition and unit measure modified: Median replaced by Average to be aligned with the KPI calculation.</li> <li>Numerator Exclusion added: <ul style="list-style-type: none"> <li>Patient days for patients in rehab phase who have achieved &gt; 90% of treated wound healing and no longer require surgical intervention OR patient days after the last sedated dressing change.</li> </ul> </li> <li>Denominator Inclusion removed: <ul style="list-style-type: none"> <li>Acute care= patients receiving active acute surgical/wound care intervention to &gt;= 90% of treated wound healing</li> </ul> </li> <li>Denominator Exclusion removed: <ul style="list-style-type: none"> <li>Patients in rehab phase with &gt;90% of treated wound healing and no longer requiring surgical intervention for wound care.</li> </ul> </li> <li>Denominator Exclusion added: <ul style="list-style-type: none"> <li>Patients who have full thickness injuries requiring Biodegradable Temporizing Matrix (BTM)/other similar products requiring integration time.</li> </ul> </li> </ul> |